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ABSTRACT 
DNA methylation is an important mode of gene inactivation in many human tumors 
including multiple myeloma (MM), where aberrant methylation of individual genes 
has been reported. However, the examination of concurrent hypermethylation of 
multiple genes has not been documented. In the current study, we studied a total of 
34 bone marrow aspirates from MM patients [M:F= 1.4:1, median age=62.5 years old, 
stage I (n=4), II (n=7) & m (n=23)], 6 human MM-derived cell lines (ARH-77, IM9, 
I 
RPMI-8226, NCI-H929, U266 and HS-Sultan) and 5 normal peripheral blood (PB) 
for DNA methylation of 6 tumor-related genes using methylation-specific-
polymerase chain reaction (MS-PCR). Results demonstrated that none of the normal 
PB showed positive methylation. In primary MM, we detected hypermethylation in 
death associated protein {DAP)-kinase, retinoic acid receptor beta (RARJ3)’ 
thrombospondin-1 (THBS-1), pi6, pl5 and Ras association domain family lA 
(RASSFIA) of 67%, 41%, 39%, 28%, 27% and 14% respectively, whereas in the 
human MM-derived cell lines, we found that hypermethylation frequency o f p l 6 was 
100% (6/6)，of THBS-1 was 50% (3/6), ofRARp and RASSFIA were 33% (2/6), of 
DAP-kinase and pl5 were 17% (1/6). Demethylation treatment with 5-aza-2'-
iii 
deoxycytidine demonstrated that hypermethylation was associated with gene 
silencing. The concurrent hypermethylation study (n=23) showed that 91% of 
primary MM had at least 1 gene hypermethylation. The hypermethylation of DAP-
kinase, RARJ3 and THBS-1 covered 83% of MM. Represented by the mean 
methylation index (MI), the extent of hypermethylation in MM was 0.32, which 
corresponded to 2 genes hypermethylation. Seventy-four percent of MM showed 
hypermethylation of at least 1 gene involved in apoptotic pathway, and the incidence 
of the defects in apoptosis was higher than the two cellular pathways (cell cycle 
regulatory and angiogenic pathways). Furthermore, a positive correlation between 
pl6 and DAP-kinase hypermethylation was revealed (Spearman correlation 
coefficient, R=+0.323,p=0.043). 
Survival analyses demonstrated a significant association between the 
hypermethylated RARfi and shorter survival period (p=0.048 by Kaplan-Meier 
method and log-rank test). Student t-tests revealed the following significant 
differences of clinical parameters between MM patients with and without methylated 
genes. DAP-kinase hypermethylation was coupled to higher immunoglobulin 
iv 
(p=0.030) and lower hemoglobin levels (/7=0.003). THBS-1 and pl6 
hypermethylation were related to decreased (p=0.040) and increased white blood cell 
(p=0.030) count respectively. Hypermethylation of pl5 was associated with higher 
platelet count (p=0.007). RASSFIA hypermethylation was related to higher lactate 
dehydrogenase (p二0.007) and calcium levels (p=0.016). Furthermore, a positive 
correlation between MI and calcium level was demonstrated (R=+0.424, /7=0.031), 
and patients showing 2 to 4 genes hypermethylation had higher calcium level than 
those showing 0 or 1 gene hypermethylation (p=0.048). The modified MI was 
P9sitively correlated to the RAR^ methylation (R=+0.425, j9=0.022). In conclusion, 
DNA hypermethylation and concurrent methylation of cancer genes are frequent 
event in MM and DAP-kinase, MR/3 and THBS-1 can be used as a panel of 







個骨髓穿刺樣本[男：：女=1.4 ： 1 ’平均年齡=62.5歲，I期（n=4)，E期（11：=：7)及 
m期(n=23) ]，6株人類多發性骨髓瘤細胞系（ARH-77 ’ IM9，RPMI-8226，NCI-
H929 ’ U266和HS-Sultan)以及5個正常外圍血樣本’用甲基化特異性多聚酶鏈 
反應(MS-PCR)方法進行6個腫瘤相關基因的DNA甲基化檢測，實驗結果証明 
锋有一例正常外圍血顯示甲基化陽性。在原發多發性骨髓瘤中檢測到的DAP-
激酶，RARP ’ THBS-1，pl6 ’ pJS和MSSF1A的高甲基化率分別爲67% ’ 
41%，39% ’ 28% ’ 27%，和14%，而在人類多發性骨髓瘤細胞系中，我們發現 
Pl6的高甲基化率爲100% (6/6) ’ THBS-1爲50% (3/6) ’ RARP和双尸M爲 
33% (2/6) ’ 0六?-激_ 1 ) 1 5爲 17% ( 1 / 6 ) �經 5-aza-2’-deoxycytidine 去甲基化處理 
証明高甲基化P基因沉默相關。甲基化的共存硏究(n=23)顯示91%的原發MM 
有至少1個基因高甲基化。D A P -激酶、R A R P和T H B S - l的甲基化佔M M的 




路）。另外，和激廢高甲基化之間存在正相關（S p e a r m a n correlation 
coefficient ’ R=+0.323 ’ p=0.043)� 





板數較高相關（p=0.007) 0 RASSF1A高甲基化與乳酸脫氣酶（p^O.007)和l!7_K平 
0^0.016)較高相關。並且’甲基化指標（M)與躬水平之間存在正相關 
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CHAPTER 1 INTRODUCTION 
1.1 Multiple Myeloma (MM) 
MM is a B-lineage hematological malignancy of clonal proliferation of malignant 
plasma cells that accumulate in the bone marrow (BM) (Figure 1.1). The tumor cells 
are characterized by secretion of a monoclonal paraprotein [immunoglobulin (Ig)] in 
serum and/or urine associated with a decrease in normal Ig levels. MM is commonly 
presented with lytic bone disease (Hoffbrand et cd,, 2001; Hideshima and Anderson, 
2002). 
1 
Figure 1.1 Multiple myeloma' (MM). Bone marrow aspirate stained with May-
Griinwald-Giemsa (MGG) from a patient with MM. The marrow is infiltrated with 
malignant plasma cells characterized by large cells with multinuclearity. 
2 
1.1.1 Epidemiology 
MM accounts for almost 13% of all hematological malignancies in Western 
populations (Mufti et al” 1996). According to the statistics in 1999，MM constitutes 
approximately 11.8% of all hematological malignancies and 0.7% of all cancers in 
Hong Kong (Hong Kong Hospital Authority, 2002). The incidence of MM is 
relatively low in Chinese compared to African Americans or Caucasians (Brain and 
Durie，2002). In general, MM is more common in male than in female and is mainly 
a disease of the elderly with high fatality (Mufti et al., 1996). Approximately 3/4 of 
patients were aged at >65 years old, and the disease accounts for approximately 1% 
of all cancer deaths in Hong Kong (Hong Kong Hospital Authority, 2002). 
1.1.2 Clinical and Pathologic Features of MM 
mm has a wide variability in clinical and pathologic features. Most of the MM 
patients present with bone pains of varying intensities, often in the lower back or ribs. 
Bone involvement results in pathological fractures affecting femur, humerus, ribs 
and sternum. Anemia, uraemia, hypercalcaemia, recurrent infections, abnormal 
bleeding tendency, hyperviscosity syndrome and sensorimotor peripheral 
3 
neuropathies are other common features observed in MM patients (Mufti et al., 1996; 
Hoffbrand et al., 2001; Brain and Dune, 2002). 
1.1.3 Diagnosis and Staging 
The diagnosis of MM depends on 3 principal findings, namely, BM infiltration by 
plasma cells (>30%); lytic bone lesions; and monoclonal protein in serum (>35 g/1 
IgG; >20 g/1 IgA) and/or urine (>1 g/24 hours). A positive diagnosis is made when a 
patient fulfills 2 of these 3 diagnostic features (Durie, 1988; Mufti et al., 1996; 
•i and e/ al,, 2001). The Durie and Salmon's staging system continues to be 
used worldwide. This staging system is based on calculating the total myeloma cell 
burden and its correlation with the major clinical parameters [hemoglobin (Hb) & 
paraprotein concentrations, serum calcium level and extent of lytic bone lesions] to 
classify the disease into 3 stages. Further subdivision into group A or B is made with 
regards to the renal function (Table 1.1) (Durie and Salmon, 1975). 
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Table 1.1 Multiple myeloma staging system (Dune and Salmon) 
Stage Criteria Myeloma cell mass 
各 (cells X 10i2/m2) 
I All of the following: <0.6 (low) 
• Hb>10g/dl 
• Serum calcium normal 
• Normal bone structure or solitary bone 
plasmacytoma only on skeletal survey 
• Monoclonal protein: 
Serum IgG<50 g/1 , 
Serum IgAOO g/1 
Urine light chains <4 g/24 hours 
II Values intermediate between Stages I and III 0.6-1.2 
in One or more of the following: > 1.2 (high) 
• Hb<8.5 g/dl 
• Serum calcium>3 • 0 mmol/1 
• Advanced lytic bone lesions 
• Monoclonal protein: 
Serum IgG>70 g/1 
Serum IgA�50 g/1 
Urine light chains >12g/24 hours 
A Serum creatinine< 180 mmol/1 
B Serum creatinine�180 mmol/1 
Hb: hemoglobin and Ig: immunoglobulin. 
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Some patients do not satisfy the diagnostic criteria for MM, but they show lower 
levels of paraprotein and BM plasma cell infiltration, and no evidence of myeloma-
related symptoms. These patients are better categorized as monoclonal gammopathy 
of undetermined significance (MGUS). MGUS is regarded as a precursor state of 
MM requiring no therapy. However, regular follow up of MGUS patients remains a 
necessity, as signs and symptoms of overt MM may ensure in approximately 30% 
(Mufti et al” 1996; Kastrinakis et al” 2000). 
14.4 Prognosis 
A variety of prognostic features had been identified for predicting the probable 
clinical course, and devising appropriate therapeutic strategies for the treatment of 
mm. The disease stage at presentation is a strong determinant of survival. 
Prognosis of MM is also determined by both the number and specific properties of 
myeloma cells in a given patient. These include growth rate, production rate of 
monoclonal proteins, production or non-production of various cytokines and 
chemicals that damage or significantly impair other tissue, organ, or body functions 
(Brain and Dune, 2 0 0 2 ) . Notably, the level of serum P 2 - m i c r o g l o b u l i n and 
6 
monosomy of chromosome 13 are significant prognostic factors (Hoffbrand et al” 
2001; Brain and Durie, 2002). 
1.1.5 Treatment 
MM is highly treatable but remains rarely curable. The choice of treatment is 
influenced by the age and general health of the patients prior therapy, and the 
presence of the complications of the disease [National Cancer Institute, 2003 
(http://www.cancer.gov/cancerinfo/pdq/treatmetn/myeloma/patients/)]. Among 
various treatment options, conventional chemotherapy using alkylating agents is 
widely adopted. MM patients are usually treated with oral melphalan combined with 
or without prednisone. Other examples of chemotherapy regimens are vincristine, 
doxorubicin, dexamethasone and cyclophosphamide (Hoffbrand et al” 2001). 
Recently, a new anti-angiogenic drug, thalidomide, has been introduced to treat 
relapsing MM patients. Thalidomide shows promising response and is now being 
evaluated in trials in both early and late disease (Hoffbrand et al, 2001; Brain and 
Durie, 2002). 
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1.2 Molecular Abnormalities of MM 
Carcinogenesis is a multistep process involving the interplay between genetic and 
epigenetic alterations (Kissil et aL, 1997; Plass, 2002). During the last decade, 
enormous researches have led to a better insight in the molecular nature of MM. For 
example, genetic instability is frequently found in MM (Drach et aL, 2000; 
Kastrinakis et aL, 2000; Kuehl and Bergsagel, 2002). Improved understanding from 
the molecular advances in MM pathogenesis would be critically useful for the 
development of novel and efficient therapeutic strategies. 
1.2.1 Genetic Alterations: Chromosomal Aberrations 
Cytogenetic studies in MM revealed the unstable nature of this disease. Complex 
sets of numerical and structural chromosomal abnormalities were found in MM 
patient samples (Drach et aL, 2000). These aberrant patterns of karyotypes were 
often accompanied with hyperdiploidy. In myeloma karyotypes, the conventional 
cytogenetic analysis by G-banding identified common chromosomal abnormalities, 
including monosomy of chromosome 1，Ip deletions, Iq duplications, complete or 
partial deletions of chromosome 13, and rearrangements in chromosomes 2，6, 8，11 
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and 14; the aberrations of chromosomes 13 and 14 were frequently recognized. 
Using modem molecular cytogenetic techniques such as interphase fluorescence in 
situ hybridization (FISH), comparative genomic hybridization (CGH) and spectral 
karyotyping (SKY), regions of abnormalities occurring in chromosomes 13 and 14 
were refined (Kastrinakis et al” 2000). 
The translocations of 14q32 involving an immunoglobulin heavy chain {IgH) locus 
were presented in most primary MM. In a diverse array of chromosomal partners for 
14q32 translocation, 4 partner chromosomes ( l lql3, 6p21, 4pl6.3 and 16q23) that 
commonly become fused to the IgH gene become the hallmarks of MM (Kuehl and 
Bergsagel, 2002). There were 3 groups of genes involved in most IgH gene 
translocations. The first group contained cyclin D1 (on l lql3) and DS (on 6p21). 
The significant overall frequency of translocations involving the cyclin D pathway 
(-20-25%) in MM highlighted the importance of this pathway (Chesi et al., 1996; 
Shaughnessy et al., 2001). The t(ll;14)(ql3;q32) translocation was the most 
common translocation in MM with a frequency of approximately 15 to 20%, which 
resulted in the upregulation of cyclin D1 expression (Pratt, 2002). Secondly, 
9 
t(4;14)(pl6.2;q32.3) translocation dysregulated a nuclear SET domain protein 
multiple myeloma SET .(MMSET), and an oncogenic receptor tyrosine kinase 
fibroblast growth factor receptor 3 (FGFR3), in which they were translocated in 
approximately 15% of MM (Chesi et al., 1997,1998b). The third group comprised 
the basic-zipper transcription factor, c-maf (on 16q23). The t(14;16)(q32.3;q23) 
translocation occurred in approximately 10% of MM, and led to an elevated c-maf 
expression (Chesi et al., 1998a). 
Monosomy or deletions of chromosome 13 were another common cytogenetic 
It 
aberrations in MM, which had been linked to shorter survival (Kastrinakis et al., 
2000). A role of monosomy 13 in MGUS progression to MM had also been 
proposed. It appears that the abnormality of chromosome 13 is an early event in MM 
transformation (Avet-Loiseau et al., 1999; Drach et al., 2000). Using interphase 
FISH, deletion of 13ql4 was found as high as 50% of MM patients (Drach et al., 
2000). The region of 13ql4 harbors the retinoblastoma (Rb) gene that participates in 
cell cycle regulation. In MM, deletions of Rb were generally monoallelic, whereas 
the biallelic deletions, inactivating mutations and lack of Rb expression seemed to 
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occur rarely in MM. As a result, it was predicted that there might be other potential 
tumor suppressor gene(s) located at 13q participating in MM tumorigenesis (Drach et 
al, 2000; Kuehl and Bergsagel，2002). The finding of a frequently deleted marker 
DS12S319 residing between Rb and D13S25, loci at 13ql4, suggested the existence 
of a candidate tumor suppressor gene telomeric of Rb (Chang et al.’ 1999). 
1.2.2 Genetic Alterations: Ras Mutations 
Ras point mutations primarily at codons 12, 13 and 61 were detected in 39% of 
newly diagnosed MM patients, and associated significantly with disease duration 
(Liu et al., 1996). Base substitutions in the N- and K-Ras were frequently detected in 
MM, but rarely seen in MGUS (Drach et al； 2000). It had been suggested that the 
activating mutations in N-Ras contributed to interleukin-6 (IL-6)-independent growth 
of myeloma cells and suppression of apoptosis (Billadeau et al., 1995). K-Ras 
mutations were related to the decreased patient survival (Liu et al” 1996). 
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CHAPTER 2 LITERATURE REVIEW 
2.1 Epigenetic Alterations: DNA Methylation 
Recently, epigenetic alterations have gained increasing recognition as important 
participants in tumor development and progression (Rush and Plass, 2002). 
Epigenetic alterations are referred as the heritable change in gene expression without 
changes in DNA sequences (Nephew and Huang, 2003). The main epigenetic 
modification in human is the DNA methylation (Esteller and Herman, 2002). It is 
the addition of a methyl group (CH3) from methyl donors such as S-adenosyl-L-
methionine (SAM) to the carbon-5 position of the cytosine ring in the CpG 
dinucleotides (cytosine 5' to guanosine) mediated by DNA methyltransferases 
(DNMTs), resulting in the generation of 5-methylcytosine (m^C) (Figure 2.1) (Singal 
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Figure 2.1 Schematic representation of the biochemical pathways for DNA 
methylation. Cytosine is methylated by DNA methyltransferase in which S-
adenosylmethioihe serves as a methyl donor. (Adapted from Singal and Ginder, 1999) 
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2.1.1 Characteristics of CpG Islands 
In human genome, CpG islands are recognized as small stretches of CpG rich DNA 
sequences with a frequency of CpG dinucleotides approximately 5 times greater than 
the genome. It is estimated that there are 45000 CpG islands, which comprise 1 to 
2% of the whole genome. The CpG islands are about 0.5 to several kilobases (kbs), 
spanning the 5'-untranslated region, promoter region, and the first few exons of most 
house-keeping and some tissue-specific genes. Approximately, 50 to 60% of all 
genes contain a promoter-associated CpG island (Gardiner-Garden and Frommer, 
1987; Antequera and Bird, 1993). It is noted that these CpG islands are normally 
m 
protected from methylation, rendering the human genes in a transcription-ready state 
(Clark and Melki, 2002; Esteller, 2002). 
2.1.2 Mechanism of Methylation-Related Gene Silencing 
DNA methylation is known to have profound effects on the suppression of gene 
activity. Nevertheless, the exact mechanism of how DNA methylation leads to gene 
silencing remains unclear, whereas intensive research is still ongoing. It is 
postulated that by means of DNA methylation, the methylated cytosine residues bind 
14 
to transcriptional repressors, such as the methyl CpG-binding protein 2 (MeCP2) that 
contains methyl CpG-binding and transcriptional repression domains. This complex 
recruits a co-repressor complex that includes histone deacetylases (HDACs), and 
leads to histone deacetylation. This event results in the formation of a stable 
repressive complex and tighter nucleosomal packing, and the final consequence is 
the chromatin compaction. As a result, transcription factors are hindered by the 
compact chromatin, and cannot access to the transcription starting site, thereby 
leading to gene silencing (Figure 2.2) (Jones and Laird, 1999; Chim et al., 2002; 
Rush and Plass, 2002; Nephew and Huang, 2003). 
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Figure 2.2 Mechanism of transcriptional silencing by DNA methylation. The 
structure of transcriptionally active chromatin is shown schematically at the top. 
Nucleosomes are shown as blue cylinders that represent the core histone complexes 
with DNA indicated by the black line wrapped around the cylinders. Yellow ovals 
(Ac) denote acetylation of histories whereas red circles indicate DNA methylation 
(Me). By DNA methylation, the transcriptional repressor methyl CpG-binding 
protein 2 (MeCP2) binds to the methylated DNA, which recruits a complex of 
transcriptional co-repressor and histone deacetylase. The consequent result is histone 
deacetylation and chromatin compaction associated with transcriptional repression. 
(Adapted from Jones and Laird, 1999) 
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2.1.3 DNA Methylation Is Important for Normal Cellular Functions 
DNA methylation occurs ..globally in normal mammalian genomes, and about 70 to 
80% of all CpG dinucleotides are heavily methylated in adult human cells (Enrlich et 
al., 1982; Siegfried and Cedar, 1997; Nephew and Huang, 2003). Although the 
5，CpG islands are normally unmethylated, there are several situations in which these 
islands become methylated in normal development, thereby silencing the expression 
of the associated genes. The methylation of 5'CpG islands are found in silenced 
genes for genomic imprinting, X-chromosome inactivation of females and ageing 
process. It is concluded that DNA methylation is essential in a diverse array of 
t* 
normal cellular processes (Jones and Laird, 1999; Chim et al” 2002; Clark and 
Wamecke, 2002). 
2.1.4 DNA Methylation Changes in Cancer Cells 
For more than 15 years, it has been recognized that the methylation patterns of tumor 
cells are significantly altered compared to those of normal cells. In cancer cells, a 
genome-wide hypomethylation as well as a local hypermethylation of certain CpG 
islands had been observed (Ehrlich, 2002; Tsou et al.，2002). The discovery of 
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extensive cancer-associated DNA hypomethylation in human genome is earlier than 
that of cancer-linked DNA hypermethylation (Ehrlich, 2002). 
2.1.5 Global DNA Hypomethylation 
The global DNA hypomethylation at the bulk of genome that is normally methylated 
has been found in many types of human cancers (Feinberg and Vogelstein, 1983; 
Clark and Melki, 2002; Ehrlich, 2002; Melki and Clark, 2002; Rush and Plass, 2002; 
Tsou et al., 2002). It was showed that various cancers often had an overall reduction 
of m^C content relative to their respective normal tissues. To date, the biological 
significance of DNA hypomethylation in carcinogenesis remains unclear (Can et al” 
1984; Denda et al., 1985; Thomas and Williams, 1992; Gaudet et al., 2003). 
Nevertheless, studies involving DNA methylation inhibitors in vivo and in vitro or 
analysis of DNMT-deficient mice indicated the importance of induced-DNA 
hypomethylation to oncogenesis (Ehrlich, 2002). Several mechanisms were 
proposed for DNA hypomethylation contributing to tumorigenesis. It was postulated 
DNA hypomethylation leading to chromosomal instability based on the observation 
that hypomethylated heterochromatic chromosome regions (contained satellite DNA 
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sequences) of chromosome 1 and 16 were deleted and translocated in human cancers 
(Narayan et a\., 1998; Qu et al., 1999). The hypomethylation of satellite DNA 
resulted in centromeric decondensation, thus enhancing chromosome recombinations 
(Jeanpierre et al., 1993; Kokalj-Vokac et al., 1993). Another possible mechanism of 
DNA hypomethylation contributing to cancer development was through the 
activation of parasitic genetic elements, such as endogenous retrotransposons (Tsou 
et al., 2002). It was from the view that loss of methylation had been observed in 
transposable elements, the long interspersed nuclear elements (LENEs) and Alu 
repeats, in cancer cells (Kochanek et al., 1995; Alves et al., 1996). The 
t* 
hypomethylation could lead to the previously silent retrotransposons to transcribe 
and mobilize throughout the genome. Consequently, it could lead to transcriptional 
activation of adjacent genes by the existing or newly transposed elements, or to the 
disruption of tumor suppressor genes (Clark and Melki, 2002; Esteller and Herman, 
2002). ‘ In addition, DNA hypomethylation was suggested to participate in 
malignancy via direct transcriptional activation of oncogenes, which might give the 
tumor cell a growth advantage (Melki and Clark, 2002). Studies showed that 
hypomethylation occurred in the body of some oncogenes such as c-myc, bcl-2, H-
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Ras and HOXll (Browett and Norton, 1989; Hanada et al., 1993; Shen et al” 1998; 
Watt et al., 2000). „ 
2.1.6 Regional DNA Hypermethylation 
In a wide variety of human malignancies, DNA hypermethylation of various genes 
were frequently observed (Esteller et al,’ 2001a; Esteller, 2002; Rush and Plass, 
2002). In contrast to hypomethylation, the occurrence of DNA hypermethylation is 
localized to the normally unmethylated 5'CpG islands, which is correlated to the 
transcriptional silencing (Melki and Clark, 2002; Rush and Plass, 2002). In vitro 
r 
experiments showed that gene expression was restored after demethylation treatment 
using demethylating agents such as 5-azacytidine (5-aza-CR) and 5-aza-2'-
deoxycytidine (5-aza-CdR). This indicated the potential reversibility of DNA 
hypermethylation (Chim et al., 2002; Melki and Clark, 2002). In conclusion, 
regional DNA hypermethylation is recognized to serve as an alternative mechanism 
of gene inactivation in tumorigenesis (Chim et al., 2002). 
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2.1.6.1 De Novo Methylation 
De novo methylation of 5'CpG islands rarely occurred in normal somatic cells. In 
contrast, cancer cells were often associated with de novo methylation (Jones and 
Laird, 1999). At present, the mechanism of de novo methylation is not yet clearly 
understood, but a recent discovery of 3 types of biologically active DNMTs seems to 
be responsible for this modification, namely, DNMTl, DNMT3a and DNMT3b. 
DNMTl is the most abundant DNMT in adult somatic cells and accounts for 
maintaining methylation patterns. On the other hand, DNMT3a and DNMT3b are 
responsible for establishing de novo methylation patterns, which are then maintained 
¥ 
by DNMTl. Furthermore, modest overexpression of the above 3 DNMTs were 
reported in human cancers as compared with the normal tissues, indicating the 
functional importance of DNMTs in tumorigenesis (Chim et al., 2002; Jones and 
Baylin, 2002). 
2.1.6.2 DNA Hypermethylation Acts As a Third Pathway to Loss of 
Function in Carcinogenesis 
In the Knudson's two-hit hypothesis, it states that two hits are required for the full 
inactivation of a tumor suppressor gene (Knudson, 1971). The phenomenon had 
21 
been demonstrated in majority of human cancers. Commonly, the two hits are the 
combination of mutation and loss of heterozygosity (LOH). Numerous studies had 
been focused on these 2 alterations for inactivation of tumor suppressors. Recently, 
the regional hypermethylation is suggested to be another hit, leading to the revision 
of this two-hit hypothesis (Table 2.1). In the revised Knudson's two-hit hypothesis, 
one allele of a tumor suppressor gene is inactivated via localized mutation or DNA 
hypermethylation at first, whereas the second hit of another allele is completed by 
either LOH or DNA methylation (Figure 2.3). The revised Knudson's two-hit 
hypothesis indicates the interplay of genetic and epigenetic alterations in 
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Figure 2.3 Revised Knudson's two-hit hypothesis. Two active alleles of a tumor-
suppressor gene are represented by the two green boxes shown at the top. The first 
step of gene inactivation is shown as a localized mutation or by DNA 
hypennethylation-associated gene repression, where the second hit is through either 
LOH or DNA methylation. Mut: mutation; Me: methylation and LOH: loss of 
heterozygosity. (Adapted from Jones and Laird, 1999) 
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2.1.6.3 DNA Hypermethylation Contributes to Tumorigenesis 
DNA methylation is recognized as a major contributor in tumorigenesis. Normally, 
typical CpG islands are devoid of methylation at any stage of development. This 
allows the expression of that particular gene, provided that appropriate transcription 
factors are present and chromatin structure is accessible to the transcription factors 
(Esteller, 2002). In cancer cells, 5'CpG islands may be abnormally methylated, 
thereby leading to transcriptional silencing of that particular gene. This is equivalent 
to loss-of-function genetic alterations such as deletion and mutation (Rush and Plass， 
2002). If a tumor suppressor gene is methylated in one allele and another allele 
shows LOH or mutation, it will be fully inactivated as stated in the revised 
Knudson's two-hit hypothesis and the consequence is the neoplastic transformation 
(Jones and Laird, 1999). In a study comparing aberrant methylation in the promoters 
of 10 tumor suppressor genes in sporadic and familial breast and colorectal cancers, 
promoter hypermethylation was a frequent event to inactivate the non-mutated alleles 
in familial cancers, but was not found in the mutated alleles (Esteller et al., 2001b). 
This indicated that DNA methylation was significant in oncogenesis by completing 
gene inactivation. 
25 
2.1.6.4 Methodologies in the Study of DNA Hypermethylation 
Methylation-specific-polymerase chain reaction (MS-PCR) is widely used to study 
the methylation status of candidate genes in tissue samples. The assay consists of 2 
parts, sodium bisulfite modification and PGR using specific primers. In the 
modification, sodium bisulfite converts the unmethylated cytosine into uracil, 
whereas the methylated one does not (Figure 2.4). This reaction differentiates the 
methylated and unmethylated DNA. Then, PCRs using methylation-specific primers 
and unmethylation-specific primers are used and the amplification depends on the 
status of methylation in the primer-recognized region. This assay avoids the use of 
methylation-sensitive restriction enzymes, thus eliminating the frequent false positive 
results due to incomplete digestion (Herman et al” 1996). Alternatively, using 
global methylation scanning techniques such as restriction landmark genomic 
scanning (RLGS), the methylation status of abundant CpG islands can be 
investigated simultaneously (Costello et al., 2000). In addition, these genome-
scanning techniques can identify novel methylated genes (Plass, 2002). 
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Unmethylated DNA 
GGG GCG GAC CGC G 
Sodium bisulfite ， 
modification I 
GGG GUG GAU UGU G 
Methylated DNA 
GGG GC^G GAC C^GC" G 
Sodium bisulfite 
modification | 
GGG GC*"G GAU C'^GC'" G 
Figure 2.4 DNA treatment with sodium bisulfite. In the bisulfite modification, all 
unmethylated cytosines are deaminated and converted into uracils, whereas 5-
methylcytosines (C") remain unaltered. 
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2.1.6.5 Single Gene Hypermethylation 
In early studies, a single gene approach was used to investigate the involvement of 
DNA hypermethylation in tumorigenesis. The list of genes with abnormal 
hypermethylation in human cancers is continued to grow rapidly (Baylin et al., 2001; 
Esteller et al., 2001a; Ehrlich, 2002; Melki and Clark, 2002; Nephew and Huang, 
2003). Table 2.2 showed the most relevant examples of hypermethylated genes in 
human cancers. They involved in different cellular pathways, including cell cycle 
[retinoblastoma (Rb), pi6, pl5 and pl4], DNA repair [breast cancer 1 {BRCAl), 
human mutL homologue 1 (hMLHl) and 0-6-methylguanine-DNA methyltransferase 
{MGMY)\ carcinogen-metabolism [glutathione S-transferase pi {GSTPl)], cell-
adherence [E-cadherin {CDHl) and H-cadherin {CDH13)] and apoptosis [death 
associated protein {DAPykinase and target of methylation-induced silencing 1 
{TMSl)] (Esteller, 2002). 
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Table 2.2 Selected genes that undergo 5'CpG island hypermethylation in human 
cancers 
Gene Function Location Tumor profile Consequences 
p16 Cyclin-dependent kinase inhibitor 9p21 Multiple types Entrance in cell cycle 
p14 MDM2 inhibitor 9p21 Colon, stomach Degradation of p53 
p15 Cyclin-dependent kinase inhibitor 9p21 Leukemia Entrance in cell cycle 
hMLH1 DNA mismatch repair 3p21.3 Colon, endometrium, Frameshift mutations 
stomach ‘ 
MGMT DNA repair of 06-alkyl-guanine 10q26 Multiple types Mutations, 
chemosensitivity? 
GSTP1 Conjugation to Glutathione 11q13 Prostate, breast Adduct accumulation? 
BRCA1 DNA repair, transcription 17q21 Breast, ovary Double strand-breaks? 
P73 p53 homologue 1p36 Lymphoma Unknown (Cisplatin?) 
ER Estrogen receptor 6q25,1 Breast Hormone insensitivity 
RAR(32 Retinoic acid receptor p2 3p24 Colon, lung, head Vitamin insensitivity? 
and neck 
RASSF1 Ras effector homologue 3p21.3 Multiple types Unknown 
VHL' Ubiquitin ligase component 3p25 Kidney, Loss of hypoxie 
hemangioblastoma response? 
Rb Cell cycle inhibitor 13q14 Retinoblastoma Entrance in cell cycle 
THBS-1 Thrombospondin-1 15q15 Glioma Neovascularization 
CDH1 E-cadherin, cell adhesion 16q22.1 Breast, stomach, Dissemination 
leukemia 
HIC-1 Transcription factor 17p13.3 Multiple types Unknown 
APC Inhibitor of p-catenin 5q21 Aerodigestive tract Activation p-catenin 
route 
SOCS-1 Inhibitor of JAK/STAT pathway 16p13.3 liver JAK2 activation 
CDH13 H-cadherin, cell adhesion 16q24 Breast, lung Dissemination? 
DAP- Pro-apoptotic 9q34.1 Lymphoma, lung, Resistance to apoptosis 
kinase colon 
TMS1 Pro-apoptotic 16p11 Breast Resistance to apoptosis 
(Adapted from Esteller, 2002) 
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2.1.6.6 Multiple Genes Hypermethylation 
As the critical role of DNA hypermethylation in carcinogenesis has been emphasized 
and the number of hypermethylated genes expands substantially, concurrent studies 
of multiple genes hypermethylation in different human tumors are rapidly emerging 
(Esteller et al., 2001a; Nephew and Huang, 2003). In the hypermethylation profiling, 
a methylation index (MI), which was a ratio of number of methylated genes to total 
number of genes being analyzed, was frequently employed in data analysis. MI 
represented the overall extent of hypermethylation from a panel of genes in 1 tumor 
sample, and the index had been used to compare the degrees of hypermethylation 
during disease progression of gastric cancers and also the degrees among different 
types of lung tumors (Toyooka et al., 2001; Kang et al., 2003). 
In a recent study of methylation of 1184 unselected CpG islands in 98 human cancers 
[breast, colon, brain, head and neck, testicular, neuroectodermal tumors and acute 
myeloid leukemia (AML)] using global methylation scanning technique RLGS, the 
methylation patterns and the degrees of methylation in cancers were tissue-specific, 
colon cancers were found to have the highest frequency of hypermethylation whereas 
30 
testicular cancers had the lowest frequency (Costello et al., 2000). Similar findings 
were demonstrated by another study using candidate gene approach in which 
promoter hypermethylation of 12 well-characterized tumor suppressor genes in 600 
primary tumors covering 15 major tumor types were investigated. They clearly 
identified tumor-specific methylation patterns (Figure 2.5) (Esteller et al” 2001a). 
Taken together, these 2 studies illustrated global patterns of hypermethylation events 
in major human cancers and indicated the existence of a unique profile of promoter 
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Figure 2.5 A. Representation of the 12-genes hypermethylation profile across 
human tumor types. The colored bar charts demonstrate unique hypermethylation 
patterns in 15 major human cancers. B. Numerical distribution of promoter 
hypermethylation according to gene and tumor type. (Adapted from Esteller et al., 
2001a) , 
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The hypermethylation of certain genes reflected their specific involvements in 
selected tumor types or groups of tumors. For example, BRCAl hypermethylaton 
was mainly found in breast and ovarian cancers, whereas the mismatch repair gene 
(hMLHl) was predominately hypermethylated in sporadic tumor types that are 
characterized with hereditary nonpolyposis colorectal cancer syndrome, i.e., 
colorectal, endometrial, and gastric tumors (Esteller et al., 1998, 2000b, 2001a; 
Herman et al., 1998; Fleisheret et al., 1999). It was proposed that these 
hypermethylation might confer a selective advantage for the survival of that 
particular cancer cell (Esteller, 2002). 
A number of genes had been demonstrated to be abnormally methylated in 
hematological malignancies (Table 2.3). For instance, pl6 but not pl5 
hypermethylation was frequent in non-Hodgkin's lymphoma (NHL), pi5 but notp/(5 
hypermethylation were often found in AML and acute lymphoblastic leukemia 
(ALL). On the other hand, high incidences of pl5 andpl6 hypermethylation were 
detected in multiple myeloma (MM). This may imply that inactivation of different 
genes contributes to the pathogenesis of different diseases, even though they all are 
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derived from hematopoietic lineage (Chim et al., 2002). In addition, the AML cases 
could be divided into 3 groups based on their substantial differences in the frequency, 
nature, and extent (density) of hypermethylation events, suggesting the presence of 
specific profiles of hypermethylation in different disease subsets (Toyota et al., 
2001). 
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Table 2.3 Aberrant promoter CpG island methylation in hematological 
malignancies 
~ J K A L L C M C ~ C M C C L L ” M D S NHL W 
(%) (%) CP (%) BT (%) (。/。） （。/。） （％) (%) 
C A L C ^ 9 0 ^ 90 % 
ER 70-90 90 50 100 60 ‘ 
p15 80-90 70-80 0 0 5 * 10 67 
p16 0-3 0-2 0 0 9 15-80 61 
HIC-1 10 50-100 50 10 25 




E-CAD 78 100 ND ND 60 ND ND ND 
AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: 
chronic myeloid leukemia; CP: chronic phase; BT: blastic phase; CLL: 
chronic lymphocytic leukemia; MDS: myelodysplastic syndrome; NHL: non-
Hodgkin's lymphoma; MM: multiple myeloma; ND: not done; *refractory 
anemia (RA)/refractory anemia with ring sideroblasts (iL4i?S)/chronic 
myelomonocytic leukemia (CMML): 0%; refractory anemia with excess blasts 
(RAEB)/refractory anemia with excess blasts in transformation (RAEB-t): 
22%. (Adapted from Chim et al； 2002) 
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2.1.6.7 Potential Clinical Applications of DNA Hypermethylation 
With the advanced understanding on DNA hypermethylation in human cancers, 
researchers begin to translate our knowledge into clinical usages. Since concordant 
hypermethylation events between tumors and exfoliative tissues (such as sputum, 
serum, etc) had been demonstrated and examination of the exfoliative tissues could 
gain insight on the nature of tumors, cancer epigenetics became a most exciting field 
of current translational cancer research (Esteller, 2002; Tsou et al., 2002). The 
translational use of DNA hypermethylation is advantageous over other DNA 
alterations such as mutations. DNA hypermethylation is easy to detect, as it occurs 
i» 
within the same region of a given gene in each tumor type. However, mutations 
often take place at multiple sites within a given gene and different mutations can be 
found in 1 type of cancer. Therefore, the nature of DNA alterations must be 
predetermined before using it as marker for examination on exfoliative samples. The 
detection of DNA hypermethylation is further facilitated by giving a ‘positive, signal 
that is easier to be detected even with normal cells contamination (Esteller et al., 
2001a; Esteller, 2002). In general, 2 major clinical areas, such as the tumor cells 
detection and prognosis, can benefit from the utilization of molecular 
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hypermethylation-based markers (Figure 2.6). 
2.1.6.7.1 Tumor Cells Detection by 5'CpG Island Hypermethylation 
The changes of 5'CpG island hypermethylation can be utilized as molecular markers 
for cancer cells detection. Only those hypermethylated genes always unmethylated 
in normal 'healthy' cells are suitable as the hypermethylation-based tumor markers 
(Esteller, 2002). 
The hypermethylation-based tumor markers are applicable in cancer screening of 
high-risk groups such as long-term smokers for lung cancers. Tumor DNA found iiT 
exfoliative tissues and blood (released from dead tumor cells) in a substantial 
fraction of cancer patients can act as the basis to assess the methylation status in 
these tissue samples (Tsou et al., 2002). Numerous biological samples such as 
sputum, broncoalveolar lavage, voided urine, saliva, semen, lymph nodes and serum 
had been explored for detection of cancer cells with hypermethylation-based tumor 
markers (Sanchez-Cespedes et al., 1999; Goessl et al., 2000; Rosas et al., 2001; 
Chan et al” 2002; Lee et al.’ 2002; Tsou et al, 2002; Wong et al” 2002). 
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Particularly, this assay for tumor cells detection had been applicable on serum 
samples of a broad spectrum of human tumors (Kawakami et al., 2000; Grady et al., 
2001; Esteller, 2002; Tsou et al., 2002). 
In addition, the hypermethylation-based tumor markers in exfoliative tissues or 
serum may serve for disease monitoring and minimal residual disease (MRD) 
detection (Chim et aL’ 2002). It was reported that there were loss of tumor markers 
from lung cancer patient sera after resection, and regain of the markers in the 
recurrence (Usadel et al； 2002). The MRD detection by MS-PCR was correlated to 
the clinical course. We previously demonstrated early detection of pi 5 methylation 
at apparent remission or its acquisition of acute leukemias during follow-up (Wong 
et aL, 2000). 
Detection of tumor cells in non-invasive biological samples can be greatly enhanced 
by employing a panel of methylation markers. Study of hypermethylation profiling 
can identify a panel of usefiil hypermethylation-based tumor markers, with a 
maximum coverage of positive methylation in a cancer type using a minimum 
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number of genes (Tsou et al., 2002). Nonetheless, further evaluation and 
optimization of utilizing hypermethylation-based tumor markers need to be 
conducted in prior to valid application in the future. 
2.1.6.7.2 Prognostic and Predictive Significances of DNA 
Hypermethylation 
In addition to the role of tumor markers, hypermethylation of cancer-related genes , 
had been suggested to serve as prognostic and predictive factors for disease 
monitoring and management (Chim et al” 2002; Esteller, 2002). Relationships 
between DAP-kinase, pi6, pi5 hypermethylation and survival had been extensively 
studied. We previously reported that DAP-kinase hypermethylation was associated 
with shorter survival duration of MM patients and this association was also 
demonstrated in patients of non-small cell lung cancer (NSCLC) (Tang et aL, 2000; 
Ng et al., 2001). In superficial bladder cancers, hypermethylation of DAP-kinase 
was associated with early recurrence of the disease (Tada et al” 2002). Aberrant 
methylation of pl6 was linked to tumor virulence in patients of colorectal cancers 
(Esteller et al” 2001c). Our previous studies showed that the overall survival of 
AML and ALL patients with pl5 methylation was notably shortened (Wong et al., 
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2000). Moreover, the 5'CpG island hypermethylation can be used to predict 
response to therapy. The most compelling evidence is provided by the study of 
MGMT methylation-associated silencing in gliomas and lymphomas. The results 
indicated that patients with the methylation likely be sensitive to the chemotherapy 
with carmustine or cyclofosfamide (Esteller et al., 2000a, 2002). As these clinical 
applications are promising, it is worthwhile to conduct prospective trials and recruit -
more cases for further validation. 
2.1.6.7.3 Therapeutic Intervention of CpG Island Hypermethylation 
The reversibility of hypermethylation-associated gene silencing provides a highly 
attractive clinical option for cancer treatment. In fact, the demethylating agent (5-
aza-CdR) improves hematopoiesis in leukemias, by directly targeting to DNMTs and 
restoring gene expression (Lubbert, 2000). Unfortunately, 5-aza-CdR appears to 
exert cytotoxic effects. Combining 5-aza-CdR with histone deacetylase (HDAC) 
inhibitors like sodium phenylbutyrate may increase efficacy as well as decrease 
toxicity, and this combination is currently assessed in clinical trials for hematological 
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Figure 2.6 Uses of 5'CpG island hypermethylation in translational studies. 
Hypermethylation of cancer genes can serve as molecular tumor markers to detect 
cancer cells in susceptible persons or recovered patients for disease monitoring. 
Using hypermethylation-based tumor marker is possible for prognosis and treatment 
response prediction. The reversible nature of DNA methylation also provides a basis 
for its therapeutic intervention. (Adapted from Esteller, 2002) 
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2.2 DNA Hypermethylation in MM and MGUS 
In MM, studies of pi6, pl5, DAP-kinase and suppressor of cytokine signaling-1 
(SOCS-I) had been reported, whereas pl6 was the most frequently analyzed gene. In 
our previous studies, we reported high frequencies of pl6 (75%) and pl5 (67%) 
hypermethylation using Southern hybridization (Ng et al., 1997). Various 
frequencies of pl6 andpl5 hypermethylation ranged from 0 to 67% and 14 to 67% 
respectively in MM were later reported by other independent groups (Urashima et al” 
1997; Tasaka et al.’ 1998; Gonzalez et al., 2000; Guillerai et al., 2001, 2003; Uchida 
et al., 2001, Kramer et al,, 2002; Mateos et al” 2002). Furthermore, we 
demonstrated high incidence of DAP-kinase hypermethylation (67%) in MM (Ng et 
al., 2001). Recently, the hypermethylation of a negative regulator of Janus 
kinase/signal transducer and activator of transcription (Jak/STAT) signaling pathway 
SOCS-1, was demonstrated with a frequency of 62.9% (Galm et al., 2003). 
Moreover, DAP-kinase, pi6 andpl5 hypermethylation had been analyzed in MGUS. 
We previously detected DAP-kinase hypermethylation in 1 out of 2 MGUS patients 
(Ng et al., 2001). One study showed pl6 hypermethylation in 19% of MGUS 
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patients, but 0% in another study (Guillerm et al； 2001; Mateos et al” 2001). pl5 
hypermethylation was demonstrated in 36% of MGUS patients (Guillerm et al., 
2001). 
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2.3 Six-Genes Panel for the Hypermethylation Study 
In the current study, 6 key-cancer genes, namely, DAP-kinase, retinoic acid receptor 
beta {RARp)^ thrombospondin-1 {THBS-1), pi6, pl5 and Ras association domain 
family lA {RASSFIA) were recruited for studying concurrent hypermethylation in 
MM. The cellular pathways regulated by these genes are detailed below. 
2.3.1 Apoptotic Pathway: DAP-kinase 
DAP-kinase is located at 9p34.1 and encodes a novel calcium/calmodulin-regulated 
serine/threonine kinase (Raveh and Kimchi, 2001). It is a 160 kDalton (kDa) protein 
that carries a death domain and ankyrin repeats, and is localized to the cytoskeleton 
(Cohen et al., 1999). DAP-kinase functions as a positive mediator of Fas-, tumor 
necrosis factor (TNF)-a-, interferon (IFN)-Y- and transforming growth factor (TGF)-
P-induced apoptotic signaling pathway (Feinstein et aL, 1995; Cohen et al., 1999; 
Jang et al., 2002). Apoptosis is a tightly regulated form of physiological cell death, 
which is triggered by the expression of cell-intrinsic suicide machinery 
(Wickremasinghe and Hoffbrand, 1999). DAP-kinase mediates apoptosis through 
dysregulated c-myc or E2F-1 that leads to up-regulation of DAP-kinase protein. The 
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activated DAP-kinase has two independent functional arms, one is wired to 
pl9ARFI murine double minute 2 {MDM2)/p53 directly, whereas the other one affects 
cytoskeleton via myosin light chain (MLC) phosphorylation and then directs to 
pl9ARF/p53. Only subsequent convergence of these 2 functional arms can result in 
/?55-responsive genes induction, and leads to caspases activation and apoptosis 
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Figure 2.7 DAP-kinase mediates oncogene-induced apoptosis via 
pl9ARF/MDM2/p53 pathway. DAP-kinase is up-regulated in response to c-myc or 
E2F-1 activation, leading to pi 9ARF/MDM2/p53 activation directly or indirectly via 
myosin light chain (MLC) phosphorylation. Convergence of the 2 pathways is 
necessary for subsequent p53 activation, resulting caspases activation and thereby 
apoptosis. (Adapted from Raveh and Kimchi, 2001) 
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DAP-kinase is suggested to possess tumor suppressor function (Kissil et al., 1997). 
It was found that DAP-kinase messenger-RNA and protein expression levels were 
below detection limits in leukemic cell lines of B-cell origin (80%), and in renal 
(40%), breast (30%), bladder (29%) carcinoma cell lines, which was in contrast to its 
ubiquitous expression in immortalized cell lines established from human normal cells. 
Interestingly, DAP-kinase was reexpressed in certain DAP-kinase negative bladder 
carcinomas and B-cell lines by treating cells with 5-aza-CdR. Thus, 
hypermethylation might be responsible for the loss of DAP-kinase expression in 
cancer cells (Kissil et al., 1997). 
I* 
To support this hypothesis, DAP-kinase was shown to be hypermethylated in various 
tumor types. Solid tumors (NSCLS, head and neck cancer, gastric and 
nasopharyngeal carcinomas) displayed frequencies of hypermethylation from 25 to 
76% (Kim et al., 2001; Rosas et al； 2001; Kwong et al., 2002; Lee et al； 2002). 
Hematological malignancies demonstrated diverse frequencies, for instance, in 
lymphomas [Burkitt's lymphoma (100%), B-cell NHL (84%), B-cell thyroid 
lymphoma (84%), T-cell NHL (0%) and Hodgkin's lymphoma (66%)]; in leukemias 
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[B-linage ALL (15%), T-linage ALL (0%), adult AML (33%), pediatric AML (4%), 
chronic myeloid leukemia (CML) (8%) and chronic lymphocytic leukemia (CLL) 
(9%)]; in plasma cell disorders [MM (67%) and MGUS (50%)] (Katzenellenbogen et 
al., 1999; Nakatsuka et al., 2000; Ng et al., 2001). Notably, B-cell malignancies had 
higher frequencies than T-cell malignancies particularly for B-cell lymphomas and 
MM (67-100%). 
The high incidence of DAP-kinase hypermethylation in MM as reported by our 
group supported apoptosis and its regulation played a role in MM tumorigenesis 
I* 
(Kissil et al., 1997; Ng et al” 2001). It is of particular relevance in MM, since MM 
is characterized by prolonged survival capacity of malignant plasma cells (Ng et al, 
2001). Generally, apoptosis is critical for immune system development, especially 
for the normal B-cell function. It is because the generation of recognition repertoires 
of B lymphocytes is dependent on the apoptotic signal to delete cells with 
inappropriate specificities. Thus, apoptosis in plasma cells is an active rather than a 
passive process. The elimination of autoreactive B lymphocytes is mediated by Fas 
system in which Fas contains a death domain in its cytoplasmic tail. Upon 
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interaction between Fas and its ligand, the death domain activates several cytosolic 
proteins and initiates - a cellular suicide cascade leading to apoptosis 
(Wickremasinghe and Hoffbrand, 1999; Ng, 2002). Plasma cells that lack of 
apoptosis may confer a growth advantage and undergo neoplastic transformation. 
2.3.2 Retinoid Signaling Pathway: RARfi 
Retinoic acid (RA) is known to possess anti-proliferative, differentiative, 
immunomodulatory and apoptosis-inducing properties (Widschwendter et al., 2000). 
The vitamin A derived retinoid, a\\-trans retinoic acid (ATRA), had been reported to 
t* 
induce apoptosis in human myeloma cell lines by altering the expression of 
interleukin-6 (IL-6) or its receptor (Ogata et al., 1994; Chen et al., 1996). IL-6 is a 
major growth and survival factor in MM, and inhibiting apoptosis in myeloma cells. 
IL-6 interacts with several factors involving in MM pathogenesis, such as adhesion 
molecules, tumor suppressor genes and oncogenes (Gado et al” 2000). 
The R4Rj3 gene is located at 3p24 and encodes a nuclear receptor mediating the 
activity of RA. RARs act as the RA-dependent transcriptional activators by binding 
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to retinoid X receptors (RXRs) in their heterodimeric forms. Subtypes of the 
receptors [RAR-a, -/?,-厂-and RXR-a, -y) display distinct expression patterns 
during development and differentiation, indicating that they may have specific 
functions. The RARs, especially RARp, induce local chromatin changes at target 
genes containing RA responsive elements (RAREs) by recruiting multiprotein 
complexes with histone acetyltransferase (HAT) and HDAC activities dynamically 
alter chromatin structure and to regulate gene expression (Widschwendter et al., 
2000; Hayashi et al” 2001). 
Down-regulated RARj3 expression had been observed in prostate, breast, cervical, 
lung and gastric cancers (Widschwendter et al., 2000; Hayashi et aL, 2001; 
Nakayama et al” 2001; Ivanova et al., 2002). Recently, RARp hypermethylation was 
demonstrated in solid tumors (SCLC and NSCLC, breast cancer, colon 
adenocarcinoma, nasopharyngeal and bladder transitional cell carcinomas) with 
frequencies of 43 to 88% (Cote et al； 1998; Virmani et al” 2000; Widschwendter et 
aL, 2000; Chan et al., 2002; Kwong et al., 2002). RARp hypermethylation was also 
detected in 47% of natural killer cell lymphoma, but none in pediatric acute 
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leukemias (ALL and acute myelogenous leukemia) (Harada et al., 2002; Siu et al., 
2002). This hypermethylation might lead to RAR/3 inactivation in cancer cells, and 
this notion was supported by the finding of reactivation of gene expression by DNA 
demethylation (Sirchia et al., 2000; Widschwendter et al., 2000; Nakayama et al., 
2001). 
2.3.3 Angiogenic Pathway: THBS-1 
THBS-1 encodes a 450 kDa trimeric glycoprotein and is mapped to 15ql5 
(Sargiannidou et al, 2001; Toyota et al,, 2001). Numerous biological activities 
f 
including effects on cell adhesion, migration, proliferation and angiogenesis have 
been ascribed to THBS-1 (Sargiannidou et al., 2001). Angiogenesis is the 
neoformation of blood vessels from pre-existing vessels, and recognized as being 
critical for tumor growth (Chavakis and Dimmeler, 2002). Besides THBS-1 
participating in angiogenesis, a wide variety of pro-angiogenic factors (vascular 
endothelial growth factor, angiopoietin-1 and -2) and anti-angiogenic factors 
(angiostatin, endostatin and vasostatin) are also responsible for the regulation of 
angiogenesis (Tanaka et al., 2002). The initiation of angiogenesis/angiogenic switch 
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is dependent on a dynamic balance between pro-angiogenic and anti-angiogenic 
factors in the immediate environment of endothelial cells (ECs). A positive balance 
in favor of pro-angiogenic factors leads to new vessels formation, whereas the 
prevalence of anti-angiogenic factors shifts the equilibrium to vessel quiescence or 
regression (Chavakis and Dimmeler, 2002). 
In human malignancies, both pro- and anti-angiogenic effects of THBS-1 had been 
demonstrated and seemed to be controversial for its role in angiogenesis. For 
instance, THBS-1 exerted pro-angiogenic effects in colorectal, pancreatic and breast 
cancers (Tuszynski and Nicosia, 1994; Yamashita et al., 1998; Kasper et a l , 2001). 
On the other hand, THBS-1 displayed anti-angiogenic properties in cutaneous and 
oral squamous cell carcinomas, bladder, breast and gastrointestinal cancers 
(Grossfeld et al., 1997; Morelli et al” 1998; Streit et al.’ 1999; Yao et al., 2000). To 
our knowledge, the role of THBS-1 in MM angiogenesis has not yet been 
investigated. 
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A postulated mechanism for the role of THBS-1 in angiogenesis is illustrated in 
Figure 2.8. THBS-1 protein and latent TGF-pl are synthesized by the growing 
tumor and ECs. Latent TGF-P1 is either directly activated by THBS-1 protein or by 
additional factors on the cell surface. Active TGF-pi signals the cell directly or 
associates with THBS-1 receptor to up-regulate the expression of genes important for 
matrix turnover such as matrix metalloproteinase-9 {MMP-9) and its inhibitor tissue 
inhibitor of metalloproteinase-1 (TIMP-l). The extent of THBS-1 up-regulated 
metalloproteinase activity is dependent on the level of THBS-1 protein, which in turn 
determines whether it will promote or inhibit angiogenesis (Sargiannidou et al.’ 
2001). 
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Figure 2.8 A postulated mechanism for the role of THBS-1 in angiogenesis. THBS-
1 protein and latent TGF-)(31 are produced from the growing tumor and endothelial 
cells (ECs), in which latent TGF-(81 is directly activated by THBS-1 protein. THBS-1 
up-regulates metalloproteinase activity of ECs and tumor cells by a mechanism 
mediated by the active TGF-|S1. Active TGF-jSl signals the cell directly or associates 
with THBS-1 receptor so as to iip-regulate the expression of a group of genes 
important for matrix turnover, such as MMP-9, TIMP-1, uPA/PAI-1 and collagen. 
The extent of THBS-1 up-regulated metalloproteinase activity is dependent on the 
degree of THBS-1 protein, which determines whether it will promote or inhibit 
angiogenesis. BAE cell membrane: bovine aortic endothelial cell membrane. 
(Adapted from Sargiaimidou et al., 2001) 
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Recently, the significant role of angiogenesis in MM had been indicated. It was 
shown that bone marrow (BM) angiogenesis was markedly increased in MM 
compared to MGUS, whereas increase in angiogenesis was correlated to the rate of 
plasma cell proliferation (Ribatti et al., 1999). Thus, angiogenesis might contribute 
to MM pathogenesis and progression by ensuring adequate tumor oxygen and 
nutrient supply and paracrine stimulation of tumor cell migration and proliferation 
(Molina and Rajkumar, 2003). 
Because THBS-1 has a role in angiogenesis, alteration of THBS-1 expression may be 
involved in human malignancies. In concordance with this postulation, decreased 
THBS-1 expression had been reported in multiple human cancers, and particularly 
DNA hypermethylation was suggested to be responsible for its inactivation 
(Clezardin et al•’ 1993; Zabrenetzky et al., 1994; Grossfeld et al., 1997; Li et al” 
1999). Studies of THBS-1 hypermethylation in solid tumors (gastric carcinoma, 
glioblastoma multiforme, carcinoid and pancreatic endocrine tumors) revealed 
frequencies of 9 to 33% (Li et al, 1999; Chan et al” 2003; Oue et al” 2003). 
Moreover, hypermethylated THBS-1 was detected in 11.3% of adult ALL patients 
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and 25% of AML patients (Toyota et al” 2001; Garcia-Manero et al., 2002b). 
2.3.4 Cell Cycle Regulatory Pathway: pl6 and pl5 
Loss of cell cycle control is a hallmark of human neoplasms. Dysregulatons of a 
number of key pathways controlling cell proliferation are essential for tumor 
development. Rb pathway is well-known for cell cycle control and the Rb protein 
arrests cells during Gl/S phase transition by repressing transcription of genes 
required for this transition. It was suggested that defective Rb pathway might be a 
universal event in human cancers (Harbour and Dean, 2000; Evan and Vousden, 
2001). 
In general, cell cycle transition is controlled by the cyclin-dependent kinases (CDKs). 
They are holoenzymes including both regulatory (cyclin) and catalytic (cdk) subunits 
and likely to recruit additional proteins. The restriction point control is mediated by 
cyclin E- and D-dependent kinases. Cyclin D interacts with two relatively long-lived 
and distinct catalytic partners CDK4 and CDK6, but cyclin D is unstable, and the 
induction, synthesis, and assembly with its catalytic partners depend upon persistent 
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mitogenic signaling. In this circumstance, cyclin D acts as a growth factor sensor, 
and forms active kinase in response to extracellular signals. Cyclin D-CDK4/CDK6 
complexes trigger Rb protein phosphorylation and cancel its growth-repressive 
function. Alternatively, the CDK inhibitors, pl6 and pi5 proteins, participate in the 
upstream control of Rb function, by competing with cyclin D for binding of 
CDK4/CDK6, thus inhibiting Rb protein phosphorylation and cell cycle progression 
(Figure 2.9) (Sherr, 2000; Bisogna et al., 2001). 
pl6 and pl5 are well-defined tumor suppressor genes, which are mapped to 9p21. 
Deletion of pl6 (particularly homozygous) and pl5 were frequently reported in 
human cancers (Jen et al.’ 1994; Kamb et al” 1994; Nobori et al., 1994). Recently, 
the hypermethylation of pl6 and pl5 were shown to be common events in a broad 
spectrum of tumor types. In solid tumors (hepatocellular carcinoma, NSCLS, 
nasopharyngeal and gastric cancers), the frequencies o f p l 6 hypermethylation ranged 
from 35 to 67%, whereas that of pl5 gene from 11 to 69% (Kurakawa et al., 2001; 
Lee et al., 2002; Kwong et al., 2002; Yang et al, 2003). In AML and ALL, pl6 
hypermethylation was a rare event (0-3%), but that of pl5 gene frequently occurred 
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(70-90%). In contrast, neitherpl6 norpl5 hypermethylation were detected in CML, 
and CLL only exhibited low frequencies of pl6 (9%) and pl5 (5%) 
hypermethylation (Chim et al., 2002). In myelodysplastic syndrome (MDS), there 
was no pl6 hypermethylation, but the disease displayed 50% of pl5 
hypermethylation (Uchida et al., 1997). Alternatively, similar frequencies of pl6 
and pl5 hypermethylation were detected in certain hematological malignancies. 
Forty-two percent of Burkitt's lymphoma had pl6 hypermethylation and 26% for 
pl5 hypermethylation (Klangby et al., 1998). For primary cutaneous B-cell 
lymphoma, 43% and 23% showedpl6 andpl5 hypermethylation respectively (Child 
et al., 2002). And in NHL, pl6 hypermethylation (15-80%) was detected more 
frequently than that of pl5 (10%) (Chim et al., 2002). Moreover, MM and MGUS 
showed diverse hypermethylation frequencies of pl6 and pl5 that had been 
summarized in Section 2.2. Notably, high incidences of pl6 and pl5 
hypermethylation but none of their deletions or mutations was shown in our previous 
studies, indicating that DNA hypermethylation played an important role in MM 
tumorigenesis (Ng et al., 1997). Furthermore, we demonstrated the transcriptional 
silencing of pl6 andpl5 in human MM-derived cell lines (Wong et al., 1998). 
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In MM, homozygous deletions and mutations of pl6 andpl5 genes were rare, and it 
was suggested that these genes inactivation were solely by hypermethylation (Ng et 
al., 1997). It was postulated that hypermethylation of p /5 and pl5 contributed to 
MM pathogenesis by dysregulating cell cycle (Ng et al., 1999). pl6 and pl5 are 
CDK inhibitors, genes inactivation lead to the accumulation of cyclin D-
CDK4/CDK6 complexes, which phosphorylate Rb protein and thereby subsequent 
Gl/S phase transition and cell proliferation. In addition, the phosphorylated Rb 
protein dysregulates the production and secretion of IL-6, a crucial growth factor in 
MM, resulting IL-6 dependent myeloma clone expansion. Rb inactivation was an 
infrequent oncogenic event in MM, pl6 and pl5 were act as important upstream 
regulators of Rb pathway to controlling plasma cells proliferation. Therefore, 
inactivation o f p l 6 andpl5 by hypermethylation played a role in MM tumorigenesis 
































































































































































































































































2.3.5 Ras Signaling Pathway: RASSFIA 
Ras protein serves as a node in the transduction of information from a variety of cell 
surface receptors to an array of intracellular signaling pathways (Vos et al., 2000). 
Mutations that lock Ras protein in its active state were frequently found in human 
cancers (Bos, 1989). Deletion of the activated Ras in tumor cell lines impaired 
tumorigenicity (Paterson et al., 1987; Shirasawa et al., 1993). Therefore, activated 
Ras protein appeared to play a key role in human cancers (Vos et al., 2000). Ras is a 
small GTP-binding protein involved in a wide range of biological effects including 
proliferation, differentiation and apoptosis. This small GTPase exists in two 
conformations, a GTP-bound active state and a GDP-bound inactive state. The 
conformational change renders Ras protein able to interact with its downstream 
effectors that mediate cellular actions of Ras. The downstream effectors are defined 
as proteins that specifically bind to the GTP-bound form of Ras protein. The best 
studied effectors are Raf protein, a serine-threonine kinase that controls the MEK-
ERK pathway; phosphatidylinositol-3 (PI-3) kinase whose activity is required for the 
activation of protein kinase B (PKB); and the members of the Ral guanine exchange 
factor (GEF) family that control the activation state of i^a^-related protein Ral. Some 
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noncatalytic proteins, such as AF-6, Rin-1 and Norel, also interact with Ras protein 
in its active state (Ortiz-Vega et al,, 2002). 
Recently, a new Ras effector homologue RASSFIA is cloned and characterized from 
the lung cancer tumor suppressor locus 3p21.3. Two major forms, RASSFIA and 
RASSFIC, are transcribed from distinct CpG island promoters (Schagdarsurengin et 
al., 2003). Studies showed that exogenous expression of RASSFIA decreased in 
vitro colony formation, suppressed anchorage-independent growth, and dramatically 
reduced tumorigenicity in vivo (Dammann et al., 2000; Burbee et al” 2001). 
t* 
Therefore, RASSFIA was suggested to participate in tumor growth inhibition. 
Studies also revealed that mutational inactivation of RASSFIA was rare, and the main 
mechanism of its inactivation was through LOH and promoter methylation (Lo et al； 
2001; Schagdarsurengin et al., 2002). RASSFIA hypermethylation was extensively 
analyzed in human neoplasms, such as ovarian, breast, lung, gastric, thyroid and 
nasopharyngeal carcinomas (40-84%) (Burbee et al, 2001; Byun et al” 2001; 
Dammann et al., 2001; Yoon et al., 2001; Kwong et al., 2002; Schagdarsurengin et 
al., 2002). In hematological malignancies, investigation of RASSFIA methylation 
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was only conducted in pediatric acute leukemias (ALL and acute myelogenous 
leukemia) (15%) (Harada er a!., 2002). 
At present, the biological role of RASSFIA is not completely understood. Since 
RASSFIA protein has a putative Ras association domain, it is suggested that 
RASSFIA protein acts as a Ras effector homologue and associates with Ras 
signaling pathway. One study showed that the C splice variant of RASSFl protein 
was directly bound to Ras protein in a GTP-dependent manner and mediated the 
apoptotic effects of oncogenic Ras (Vos et al., 2000). On the other hand, another 
study indicated no direct interaction between RASSFIA protein and Ras protein or 
six other Ras GTPases, RASSFIA protein heterodimerized with another novel Ras 
effector Norel, and thereby associated with Ras-like GTPases (Ortiz-Vega et al., 
2002). In addition, a proapoptotic protein kinase MSTl, forms complexes with 
RASSFl and Norel proteins to initiate apoptosis. It is hypothesized that the 
RASSFl/MSTl protein complex heterodimerizes with Norel/MSTl protein complex 
and mediates the apoptotic effect of Ras (Figure 2.10) (Khokhlatchev et al” 2002). 
Alternatively, RASSFIA was also shown to prevent cyclin D1 accumulation, and 
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function as a negative regulator of cell proliferation through inhibition of Gl/S phase 
transition (Shivakumar et al., 2002). Taken together, the functional pathways of this 
protein involved for tumor inhibition remains to be determined. 
f 
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Figure 2.10 A hypothesis for RASSFIA mediates apoptosis in Ras signaling 
pathway. RASSFIA protein forms complex with a proapoptotic protein kinase MSTl, 
which may function physiologically as a proapoptotic effector. RASSFIA/MSTI 
protein complex may also heterodimerize with NOREl/MSTl protein complex and 
thereby bind to RasGTP indirectly, which results apoptosis initiation. (Adapted from 
Khokhlatchev et al., 2002) 
66 
CHAPTER 3 BACKGROUND OF STUDY 
3.1 Rationale 
Recently, hypermethylation of various tumor-related genes has been demonstrated in 
human cancers, which is recognized as an important mechanism contributing to 
tumorigenesis (Esteller et al.’ 2001a). DNA hypermethylation has an immediate 
consequence on gene transcription, and is regarded as an alternative mechanism for 
gene inactivation as stated in the revised Knudson's two-hit hypothesis (Jones and 
Laird, 1999). Previously, we have shown high incidences of hypermethylation of 
death associated protein (DAF)-kinase, pl6 and pl5 in multiple myeloma (MM), 
which play a role in MM pathogenesis (Ng et a!., 1997，2001). Besides 
investigations on individual gene hypermethylation, studies of hypermethylation of 
multiple genes in human neoplasms are emerging recently (Esteller et al., 2001a; 
Nephew and Huang, 2003). Nonetheless, to our knowledge, the hypermethylation 
profiling of MM has not yet been documented. Hypermethylation profiles were 
successfully employed to define disease-specific pattern, develop diagnostic, and 
prognostic markers (Esteller et al., 2001a; Toyooka et al., 2001; Chan et al., 2002; 
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Garcia-Manero et al., 2002a). In acute myeloid leukemia (AML), disease subgroups 
were classified based on the differences in the frequency, nature and extent of 
multiple hypermethylation events (Toyota et al., 2001). Therefore, it may be 
beneficial to study hypermethylation profiling in MM, to reveal distinct methylation 
) 
pattern for disease subgroups classification and identification of tumor and 
prognostic markers of the disease. In this study, we examined the methylation status 
of 6 cancer-related genes in MM for hypermethylation profiling. As DAP-kinase, 
pl6 and pl5 displayed high frequency of hypermethylation, they were recruited in 
the panel of genes, with an aim to develop tumor markers for MM (Ng et al” 1997， 
t* 
2001). Retinoic acid receptor beta (RAR阶,thrombospondin-1 {THBS-1) and Ras 
association domain family lA (RASSFIA) were also included. These genes 
participate in different pathways relating to tumor transformation. DAP-kinase and 
RAR^ possess apoptotic function; THBS-1 participates in angiogenesis; pl6 and pl5 
are cell cycle regulators; and RASSFIA plays a role in Ras signaling pathway, 
mediating apoptotic and cell cycle regulatory fiinctions (Sherr, 2000; Widschwendter 
et al., 2000; Raveh and Kimchi, 2001; Khokhlatchev et al., 2002; Tanaka et al； 2002; 
Shivakumar et aL, 2002). 
68 
3.2 Hypothesis 
We hypothesized that aberrant methylation was a frequent event which might affect 
multiple genes concurrently. Hypermethylation profiling studies would reveal 
specific methylation patterns. By studying a panel of genes in MM, we aimed to 
evaluate a maximum coverage of positive hypermethylation in the MM samples with 
potentially the least number of markers to assay ultimately. In addition, we 
hypothesized that aberrant methylation was associated with disease severity, 
prognosis and survival. 
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3.3 The Objectives of Study 
The objectives of the current study are stated as follows: 
1. To determine hypermethylation status of 6 tumor-related genes, DAP-kinase, 
RA即,THBS-1 ’ pl6, pl5 and RASSFIA in 6 human MM-derived cell lines and 
34 Chinese MM using methylation-specific-polymerase chain reaction (MS-
PCR). 
� 2. To investigate potential associations between the methylation status and clinical 
parameters, in order to 
a. reveal MM-specific hypermethylation pattern, 
b. develop the panel of hyperaiethylation-based tumor markers for MM, and 
c. predict prognosis. 
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CHAPTER 4 MATERIALS AND METHODS 
4.1 Culture of Human Multiple Myeloma (MM)-derived Cell Lines 
ARH-77, IM9, RPMI-8226, NCI-H929, U266 and HS-Sultan human MM-derived 
cell lines were purchased from the American Type Culture Collection (Manassas, 
VA). The cells were maintained in RPMI-1640 medium (Sigma, St. Louis, MO) at 
pH 7.2，supplemented with 2 g/1 sodium bicarbonate (Sigma), 4 g/1 glucose (Sigma), 
2 mM L-glutamine (GIBCO, Grand Island, NY) and 100 U/ml 
penicillin-streptomycin (GIBCO). Five percent heat-inactivated fetal bovine serum 
(FBS) (GIBCO) and 1 mM sodium pyruvate (GIBCO) were added in the culture 
medium for ARH-77, IM9, RPMI-8226 and U266. Culture medium containing 
10% FBS and 0.05 mM 2-mercaptoethanol (Invitrogen, Japan) was used for 
NCI-H929. HS-Sultan was maintained in culture medium containing 5% FBS. 
All the cell cultures were kept at 37°C and 5% carbon dioxide atmosphere. 
NCI-H929 was passaged every 5 days, whereas other cell lines were passaged every 
3 days. Cell cultures in the log phase were subjected to DNA extraction for 
subsequent methylation-specific-polymerase chain reaction (MS-PCR) analysis. 
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4.2 Demethylation Treatment 
U266 and HS-Sultan were treated with the demethylating agent, 
5-aza-2'-deoxycytidine (5-aza-CdR) (Sigma). There were 5 x 10^  cells treated with 
5-aza-CdR in a final concentration of 0, 1，3，5 and 10 juM for 96 hours. At the end 
of the treatment, the cells were harvested for total RNA extraction and subsequent 
reverse transcription-PCR (RT-PCR) analysis. 
4.3 Patient and Control Samples 
Bone marrow (BM) aspirates from 34 Chinese MM patients in The Prince of Wales 
Hospital, Shatin, Hong Kong between 1996 and 2000 were recruited in this study 
with informed consent. The diagnosis and staging classification of MM samples 
were made following the criteria by Dune and Salmon (Dime and Salmon, 1975; 
Dune, 1988). The MM patients were followed up regularly and given standard 
treatment. Their clinical data were retrieved at the end of 2002 for subsequent 
statistical analyses. Five normal peripheral blood (PB) samples from healthy 
donors and 6 BM aspirates from patients with reactive plasmacytosis served as 
normal controls. Universal methylated DNA (Intergen, New York, NY) was used as 
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a positive methylated control. 
4.4 DNA Extraction 
Buffy coat fractions were isolated from 34 BM aspirates of MM patients and 5 
normal PB samples. Genomic DNA was extracted from the buffy coat fractions and 
the cell lines according to the standard sodium dodecyl sulfate-proteinase K 
(Amersham Biosciences, UK) treatment for protein digestion, 
phenol/choloroform/isoamyl alcohol (Amersham Biosciences) extraction and ethanol 
(EtOH) precipitation method (Sambrook and Russell, 2001). 
f 
4.5 MS-PCR 
Extracted genomic DNA was subjected to access the methylation status of death 
associated protein (J)AF)-kinase, retinoic acid receptor beta (RAR^), 
thrombospondin-l {THBS-1\ pi6, pl5 and Ras association domain family lA 
(RASSFIA) using MS-PCR as previously described (Herman et al, 1996). 
MS-PCR is consisted of bisulfite modification and subsequent PGR amplification. 
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Genomic DNA was bisulfite-modified using CpGenome DNA Modification Kit 
(Intergen) in accordance to the manufacturer's instructions. Only the unmethylated 
(U) but not methylated (M) cytosines were converted into uracils, resulting U- and 
M-sequences that could be differentiated using sequence-specific U-primer and 
M-primer sets. In brief, DNA was first denatured with freshly prepared 3 M sodium 
hydroxide and subjected to the modification. The denatured DNA was treated with 
freshly prepared 3 M sodium bisulfite (Reagent I) pH 5.0 at 50°C for 16 hours to 
convert the unmethylated cytosines into uracil sulphonate intermediates. The 
modified DNA was then bound to the micro-particulate carrier (Reagent III) and 
desalted by 70% EtOH. The conversion to uracil was completed by treatment of 20 
mM NaOH/90% EtOH via alkaline desulphonation, and the modified DNA was 
finally eluted by heating in milliQ water. 
Subsequent PGR amplification of the bisulfite-modified DNA was conducted using 
U- and M-primer sets for the 6-genes panel. The primer sequences were shown in 
Table 4.1. Two bisulfite-modified DNA were amplified in a total volume of 25 
/xl PGR reaction mixture containing IX PGR buffer (PE Applied Biosystems, Foster 
74 
City, CA), 2 mM magnesium chloride (MgCl�）(PE Applied Biosystems), 0.25 mM 
of each deoxynucleotide triphosphates (dNTPs) (Roche, Germany), 1 fiM of each 
primers and 1 U AmpliTaq Gold polymerase (PE Applied Biosystems). PGR was 
carried out in a thermal cycler 2700 (PE Applied Biosystems) using following 
temperature profiles: an initiation denaturation at 95°C for 10 minutes, followed by 
40 cycles of denaturation at 95°C for 1 minute, annealing at specific temperature for 
each primer pair for 1 minute and an extension at 72°C for 1 minute, and completed 
by a final extension at 72°C for 10 minutes. The annealing temperature and PGR 


























































































































































































































































































































































































































































































































































































































PGR products (10 jLtl) with 6X loading dye (0.1% bromophenol blue; 0.1% xylene 
cyanol FF; 30% gyclerol) (Sigma) were electrophoresed onto 10% non-denaturing 
polyacrylamide gels, stained with 0.02% ethidium bromide, and visualized under UV 
illumination. In each assay, the positive methylated and negative reagent controls 
were included, and a DNA size marker of (j)X174 RF DNA/Hae III fragments 
(GIBCO) was used to determine the PGR product size. Experiments were repeated 
at least 2 times in order to confirm the methylation status of each case. 
4.6 Plasma Cell Isolation 
Mononuclear cells (MNCs) from 6 BM aspirates of patients with reactive 
plasmacytosis were isolated by Ficoll density gradient centrifugation. Ficoll 
Paque™ Plus (Amersham Biosciences) was added into BM aspirate/saline mixtures 
in a ratio of 1 to 2，then centrifiiging at 1,400 rpm for 30 minutes. After 
centrifugation, MNCs that localized in the middle layer were collected for 
subsequent plasma cell isolation. 
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Plasma cells were immunomagnetic sorted from MNCs using MiniMACS Kit 
(Miltenyi Biotec, Bergisch Gladbach, Germany). Super-paramagnetic MACS 
CD 138 Microbeads, conjugated to monoclonal mouse CD 138 antibody, were used to 
label plasma cell surface antigens. A strong permanent magnet of the MiniMACS 
Separation Unit served to create a high-gradient magnetic field for the magnetized 
cell sorting. The labeled plasma cells were retained in the MS Column in the 
presence of magnetic field. After removal of the magnet, plasma cells were eluted 
by phosphate buffered saline (Sigma) containing 0.5% bovine serum albumin 
(Sigma). 
4.7 RNA Extraction and RT-PCR 
The sorted plasma cells and 5-aza-CdR treated cells were subjected to total RNA 
extraction using Trizol reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer's instructions. Two fig total RNA were used for reverse-transcription 
(RT) reaction. RT was performed in 20 fil reaction volume containing IX PGR 
buffer, 5 mM MgCl!，1 mM of each dNTPs, 2.5 fjM of random hexamers (PE 
Applied Biosystems), 20 U RNase inhibitor (PE Applied Biosystems) and 50 U 
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murine leukemia virus reverse transcriptase (PE Applied Biosystems). It was 
carried out in a thermal cycler 2700 using following temperature profile: primer 
attachment at 22°C for 25 minutes, followed by complementary DNA (cDNA) 
synthesis at 42°C for 65 minutes and completed by enzymes inactivation at 92°C for 
2 minutes. 
Resultant cDNA was subjected to PGR for DAP-kinase, THBS-l, RASSFIA and 
glyceraldehyde-3-phosphate dehydrogenase {GAPDH) in normal plasma cells, cell 
lines with and without 5-aza-CdR treatment. In brief, PGR mixture contained 1 /xl 
resultant cDNA, IX PGR buffer, 2 mM MgCl2,0.2 mM of each dNTPs, 0.5 /xM of 
each primers, 0.5 U AmpliTaq Gold polymerase in a final volume of 20 pil, and the 
PGR was performed in the thermal cycler 2700. PGR was started at 95°C for 6 ‘ 
minutes, followed by 35 cycles at 94°C for 1 minute, at specific temperature for each 
primer pair for 1 minute and at 72°C for 1 minute, and finally completed at 11。C for 
4 minutes. The primer sequence, corresponding annealing temperature and PCR 
product size were listed in Table 4.2. PCR products (20 /xl) with 6X loading dye 
were separated on 2% agarose gels, stained with 0.2% ethidium bromide, and 
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visualized under UV illumination. The quality of RNA samples was assessed by 
GAPDH RT-PCR. To-confirm the accuracy of amplification, PGR products were 
purified using QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany) and 






















































































































































































































































































A methylation index (MI), the number of methylated genes over the total number of 
analyzed genes (n = 6), was calculated for each case. 
Nm 
Methylation Index (MI)= 
N t 
Nm= number of methylated genes; 
N t= total number of analyzed genes, i.e., 6 genes 
For the examination of correlations between the 6 genes methyation status and MI, a 
modified MI was used. It was equaled to the number of methylated genes, 
excluding the gene being analyzed in the current correlation analysis, over the 
number of other analyzed genes (i.e., 5 genes). 
Nm’ 
Modified MI = 
NT-1 
Nm，= number of methylated genes that excluding the gene 
. being analyzed in the current correlation study; 
NT-1= total number of other analyzed genes, i.e., 5 genes 
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All statistical analyses were performed using SPSS software (Version 10.0, SPSS, 
Chicago, IL). Correlation analyses among methylation status, clinical data and MI 
were made by Spearman correlation rank test. Associations between methylation 
status and clinicopathologic parameters were analyzed by Fisher's exact test (for 
categorical data). Student t-test was used to examine the mean of clinical 
parameters (for numerical data) between patients with methylated and unmethylated 
genes. Survival data was analyzed using Kaplan-Meier method, and p-value was 
computed by the log rank test. For all statistical tests, /?-valiie less than 0.05 were 
considered to be significant. 
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CHAPTER 5 RESULTS 
5.1 Patient Characteristics 
A total of 34 Chinese multiple myeloma (MM) patients were analyzed for death 
associated protein {DAP)-kinase, retinoic acid receptor beta {RARP), 
thrombospondin-1 {THBS-l\ pi6, pl5 and Ras association domain family lA 
(RASSFIA) hypermethylation by methylation-specific-polymerase chain reaction 
(MS-PCR). The clinical data of the 34 MM patients were summarized in Table 5.1. 
Clinical parameters include gender, age, presentation status, staging, histology, 
immunoglobulin (Ig) isotypes, involvement of plasmacytoma, bone marrow (BM) 
plasma cell infiltration, complete blood counts, biochemistry results and survival 
status. In brief, the male to female ratio was 1.4 to 1，with a median age of 62.5 
years old (range: 29-89 years old). Twenty-four primary MM were analyzed at the 
time of diagnosis, while 10 at posttreatment (median treatment duration: 8 months). 
According to the Salmon and Dune's staging classification (Dune and Salmon, 
1975), 23 MM patients had stage III, 7 had stage II and 4 had stage I disease. 
Histological information was only obtained for 28 MM patients, in which 6 were 
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classified as mature, 12 as intermediate, and 10 as blastic. Study of the Ig isotypic 
profile revealed 13 GK, 6 G入，7 AK, 2 AX, 5 K and 1 X, and the mean Ig was 
40.54士 18.16 g/1 (range: 9.80-85.60 g/1). Eleven patients had plasmacytoma. 
Mean percentage of plasma cell infiltration was 56.12±25.76% (range: 15-100%). 
Complete blood count revealed a mean hemoglobin (Hb) of 9.01 ±2.59 g/dl (range: 
4.50-14.80 g/dl), a mean white blood cell (WBC) count of 6.91 土2.64 x 10 /^1 (range: 
3.20-14.20 X 10 /^1), and a mean platelet count of 229.36土 102.60 x 10V\ (range: 
42.00-474.00 x 10 /^1). Biochemistry data showed that the mean albumin was 
27.69±7.22 g/1 (range: 17.00-42.00 g/1), the mean lactate dehydrogenase (LDH) was 
194.00±106.48 U/1 (range: 61.00-542.00 U/1) and the mean calcium was 2.74土0.46 
mmol/1 (range: 2.20-4.27 mmol/1). In skeletal surveys, 17 patients showed multiple 
(22) skeletal lesions, 5 showed one site lesion, and 9 patients had no lesions. By the 
end of 2002, 7 patients were still alive (median follow-up duration: 64 months), 25 
were dead (median survival: 16 months) and 2 were defaulted. 
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Table 5.1 Clinicopathological data of 34 MM patients 
Clinical parameter Number 
Gender 
Male 20 
Female 14 (M: F ratio=1.4:1) 
Median age 62.5 years old (range: 29-89 years old) 
Presentation status 
At diagnosis 24 




















Mean plasma cell infiltration 56.12±25.76% (range: 15.00-100.00%) 
Mean hemoglobin 9.01 ±2.59 g/dl (range: 4.50-14.80 g/dl) 
Mean white blood cell count 6.91±2.64 x 109/1 (range: 3.20-14.20 x 109/1) 
Mean platelet count 229.36±102.60 x 109/1 (range: 42.00474.00 x 109/1) 
Mean albumin level 27.69±7.22 g/1 (range: 17.00-42.00 g/1) 
Mean lactate dehydrogenase' 194.00±106.48 U/l (range: 61.0-542.00 U/l) 
Mean calcium level 2.74±0.46 mmol/l (range: 2.20-4.27 mmol/1) 
Skeletal surveys . 
Multiple lesions (>2) 17 
One lesion 5 
No lesion 9 
Survival (last updated at the end of 2002) 
Alive 7 (median follow-up duration: 64 months) 
Dead 25 (median survival: 16 months) 
Unknown 2 (defaulted) 
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5.2 Single Gene Hypermethylation 
Hypermethylation study of 6 cancer-related genes, DAP-kinase, RAR/3, THBS-1, pi6, 
pl5 and RASSFIA in 5 normal peripheral blood (PB), 6 human MM-derived cell 
lines and 34 primary MM was conducted using MS-PCR. 
5.2.1 Normal PB Did Not Show Methylation 
In all normal PB controls, no methylated-band was detected, but all showed 
unmethylated-bands. Representative gel photos of the MS-PCR analysis were 
shown in Figure 5.1. 
5.2.2 DNA Hypermethylation in Human MM-derived Cell Lines 
The entire panel of genes showed varying degrees of DNA hypermethylation in the 6 
human MM-derived cell lines. pl6 was methylated the most frequently, where 
hypermethylation of DAP-kinase and pl5 genes were the least. Frequency of pl6 
hypermethylation was 100% (6/6), THBS-1 was 50% (3/6), RARp and RASSFIA 
were 33% (2/6), DAP-kinase and pl5 were 17% (1/6) (Table 5.2). In particular, in 
pl6 hypermethylation, nearly all (5/6) cell lines were completely methylated 
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(NCI-H929, RPMI-8226, U266, HS-Sultan and ARH-77), whereas only IM9 was 
partially methylated. -For THBS-1, complete methylation was detected in 1 (IM9) 
out of 3 methylated cell lines, and the other 2 cell lines (NCI-H929 and IM9) showed 
partial methylation. Among 2 cell lines showed RASSFIA hypermethylation, U266 
showed complete methylation but HS-Sultan demonstrated partial methylation. 
Both DAP-kinase and pl5 had complete methylation in HS-Sultan. RAR^ only 
displayed partial methylation that detected in NCI-H929 and HS-Sultan. Gel 
photos of the MS-PCR analysis were shown in Figure 5.1. Specificity of the 
methylated-band in each gene was confirmed by the correct sized-methylated- band 
yielded from positive control (universal methylated DNA), whereas the quality of 
MS-PCR was ensured by the empty bands obtained from negative reagent control. 
The human MM-derived cell lines demonstrated different number of methylated 
genes. HS-Sultan had methylation at full panel of genes (6/6), NCI-H929 had 3 
methylated genes, U266 and IM9 had 2 methylated genes, RPMI-8226 and ARH-77 
had 1 methylated gene. In particular, HS-Sultan had 4 complete (DAP-kinase, 
THBS-1, pl6, pl5) and 2 partial {RAR&, RASSFIA) methylation, where NCI-H929 
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exhibited 1 complete {pl6) and 2 partial (RAR3, THBS-1) methylation. 
RPMI-H929 (pI6), U266 (pi6, RASSFIA) and ARH-77 {pl6) only showed complete 
methylation, and IM9 {THBS-I,pl6) simply had partial methylation. 
5.2.3 DNA Hypermethylation in Primary MM 
The frequency of 6 cancer genes hypermethylation in 34 primary MM was 
determined. DAP-kinase exhibited the highest hypermethylation frequency whereas 
RASSFIA exhibited the least. Frequency of DAP-kinase hypermethylation was 
67% (22/33; 4 stage I，7 stage II and 22 stage III), RARfi^as 41% (11/27; 4 stage I, 5 
stage II and 18 stage III), THBS-1 was 39% (9/23; 4 stage I, 5 stage II and 14 stage 
111% pi6 was 28% (8/29; 4 stage I，5 stage II and 20 stage m\pl5 was 27% (8/30; 4 
stage I, 6 stage H and 20 stage III) and RASSFIA was 14% (4/29; 4 stage I，5 stage II 
and 20 stage III) (Table 5.3). Representative gel photos of the MS-PCR analysis 
were shown in Figure 5.1. 
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DAP-kinase 
ARH U266 RPMI NCI IM9 HS P3 P4 P5 P6 PB Uni-M Water 
—LLJ_—yjLU-J LU/liL_MU_MLLi/IU_J/lU_i/lL01LLJAL01U_M 
B B H H B ^ H H B H H 
RARP 
NCI ARH U266 RPMI IM9 HS P3 P6 P27 P29 PB Uni-M Water 
• JLJ l 01LLML01U_JlLLJ/lUJVlU_JdLLJdLLMU_JlU_j/l 
146^ i ^ m ^ ^ m i i ^ n i i i H i H B ^ B ^ ^ m i ^ ^ H 
THBS-1 
NCI IM9 U266 RPMI ARH HS P5 P3 P11 P19 PB Uni-M Water 
LUl LLMUJyiU_MUJyiU_My_J!LLJlU_MLLJlLLJlLLJiy_M 
pl6 
ARH IM9 U266 RPMI NCI HS P3 P9 P4 P23 PB Uni-M Water 
LUl y_Jl U M U M U M U M U M U M U M U M U M U M U M 
IM9 ARH U266 HS RPMI NCI P3 P9 P4 P25 PB Uni-M Water 
U_MLLMLO!UMUMUMU_MUjy|y_MU_MU_MU_MO^ 
i 兹二 H H S H D H H H ^ H H I H I I H H I 
RASSFIA 
RPMI U266 IM9 ARH NCI HS P20 P14 P10 PI PB Uni-M Water 
J L M LLM LL-M UJTLLJ/l L L M L 0 1 L L J d L L J i y _ M L 0 1 L L M 0 1 
Figure 5.1 Methylation analyses of DAP-kinase, RAR/3, THBS-1, pi6, pl5 and 
RASSFIA in normal peripheral blood (PB), human MM-derived cell lines and 
primary MM by methylation-specific-PCR. This figure shows the gel photos of 
representative samples. U indicates the presence of unmethylated genes whereas M 
denotes the presence of methylated genes. Universal methylated DNA (Uni-M) and 
reagent mixture (Water) served as the positive and negative controls respectively. 
MS-PCR product size (U and M) of each gene was denoted on the left. ARH: 
ARH-77; HS: HS-Sultan; RPMI: RPMI-8226; NCI: NCI-H929 and P: patient. 
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Table 5.2 Frequencies of hypermethylation of 6 cancer genes in 6 human 
MM-derived cell lines analyzed by methylation-specific-PCR 
DAP-kinase RAR/3 THBS-l pl6 pi 5 RASSFIA 
NCI-H929 ~ 
RPMI-8226 ^ 
腦 — • 
HS-Sultan 
ARH-77 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
IM9 
Frequency of 1/6 2/6 3/6 6/6 1/6 2/6 
hypermethylation (17%) (33%) (50%) (100%) (17%) (33%) 
:unmethylation JJ^ ipartial methylation xomplete methylation 
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Table 5.3 Frequencies of hypermethylation of 6 cancer genes in 34 primary MM 
analyzed by methylation-specific-PCR 
Gene DAP-kinase RARfi THBS-1 pl6 pl5 RASSFIA 
Frequency of 67% 41% 39% 28% 27% 14% 
hypermethylation (22/33) (11/27) (9/23) (8/29) (8/30) (4/29) 
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5.3 Demethylation Treatment 
Association of hypermethylation and transcriptional silencing was demonstrated by 
treating cells with demethylating agent 5-aza-2'-deoxycytidine (5-aza-CdR) and 
conducting reverse transcription-PCR (RT-PCR). Only cell lines with complete 
methylation were used for the demethylation treatment, for instance, HS-Sultan 
showed complete methylation of DAP-kinase and THBS-1. Demonstrated by 
RT-PCR, HS-Sultan lacked DAP-kinase and THBS-1 expression before 5-aza-CdR 
treatment. However, the expression of DAP-kinase and THBS-1 was restored after 
5-aza-CdR treatment for 96 hours at 4 concentrations (1’ 3，5 and 10 jiM). 
Additionally, U266 exhibited RASSFIA complete methylation and did not show 
RASSFIA expression initially. Treating U266 cells with 5-aza-CdR using the same 
conditions as stated above, transcripts of RASSFIA were detected. Normal plasma 
cells were expected to express normal transcripts so as to serve as positive control, 
which was then used to confirm the specificity of the bands showing in the treated 
cell lines. Empty band yielded from negative reagent control was used to ensure the 
quality of RT-PCR (Figure 5.2). To sum up, these data indicated associations 
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between DAP-kinase, THBS-1, RASSFIA hypermethylation and transcriptional 
silencing in MM cells.-
1. . 
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Before treatment After 5-aza-CdR treatment 
RASSFIA 
Figure 5.2 Expression analysis of DAP-kinase, THBS-1 and RASSFIA by 
RT-PCR in human MM-derived cell lines before and after demethylation 
treatment. DAP-kinase, THBS-1 and RASSFIA were reexpressed in 
respective cell lines associated with complete methylation after treating cells 
with demethylating agent 5-aza-2 ‘ -deoxycytidine (5-aza-CdR) for 96 hours. . 
Normal plasma cells (NP) showed transcripts of DAP-kinase, THBS-1 and 
RASSFIA. Reagent mixture (Water) served as negative control. HQ： HS-
Sultan before demethylation treatment; H96hAl, 3, 5 & 10: HS-Sultan after 
demethylation treatment for 96 hours at 1，3，5 and 10 pM 5-aza-CdR; UQ. 
U266 before demethylation treatment and U96hAl, 3, 5 & 10: U266 after 
demethylation treatment for 96 hours at 1, 3, 5 and 10 \iM 5-aza-CdR. 
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5.4 Concurrent Hypermethylation 
Only 23 primary MM -yielded adequate tissue for the concurrent hypermethylation 
analysis of 6 cancer-related genes. A summary of concurrent methylation status in 
the same cohort of 23 MM patients was shown in Table 5.4. Results showed that 
all of the 6 genes displayed aberrant methylation in primary MM with varying 
frequencies. Moreover, DNA hypermethylation was found in only single target 
gene as well as multiple genes concurrently in each MM. 
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Table 5.4 Summary of the concurrent methylation status of 6 cancer genes in 23 
primary MM analyzed by the methylation-specific-PCR 
Patient DAP-kinase RASfi THBS-l pl6 pl5 RASSFIA 
BBBBaaaBBBBBBB BBSSBBaaBBSSSBaBBBBSB ^aBBXSSSBB^^BMBata ^B^^^^^gaggg^^^^m SBB^B^BBSSI^^B a B S S B ^ ^ ^ B m B B ^ ^ ^ ^ m g ^ ^ ^ B ^ ^ g g g 
M M 
P7 I I 
^ ^ Z Z J B H B t l l l Z Z Z Z Z Z I l H B ^ ^ ^ ^ 
PIO I I 
p " ^ J — — 7 • 
P20 m ^ m 
P22 I J U I I U U l 
^ ^ P — — p w 
d H t a i i i i i i l H i t i z j i i H ^ 
P28 
Filled boxes: methylated genes and blank boxes: unmethylated genes. 
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By summarizing the number of methylated genes in each MM, it revealed that 0 up 
to a maximum of 4 gene(s) were aberrantly methylated, in which 9% (2/23) of 
primary MM methylated at 0 gene, 35% (8/23) at 1 gene predominantly, 26% (6/23) 
at 2 genes, 17% (4/23) at 3 genes and 13% (3/23) at 4 genes (Figure 5.3). No 5 or 6 
genes hypermethylation was detected. Results showed that 91% (21/23) of MM 
patients had at least 1 gene hypermethylation, and 2 to 4 genes hypermethylation was 
found in 56% of primary MM. Results also revealed that the hypermethylation of 3 
cancer-related genes (DAP-kinase, RAR& and THBS-1) covered 83% of primary MM. 
t 
The extent of DNA hypermethylation was indicated by the methylation index (MI), 
which was the fraction of number of methylated genes over total number of genes 
being analyzed. According to the number of genes methylated in primary MM, 
they were divided into 5 groups possessing different MI, i.e., 0, 0.17’ 0.33, 0.50 and 
0.67 (Figure 5.3). When the MI was increasing, the number of patients methylated 
at higher gene number (3 or 4 genes) was decreasing. The mean MI was 0.32, 
which corresponded to 2 genes hypermethylation in the primary MM. 
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^ 30- B B H 
^ H i J U 
immmmmi 
0 ( 0 ) 1 (0.17) 2 (0 .33 ) 3 (0 .5 ) 4 (0 .67 ) 
Number of methylated genes/Ml 
Figure 5.3 Percentage distribution of number of methylated genes/Ml 
in 23 primary MM. Ninety-one percent of primary MM had at least 1 




To investigate the involvement of cellular pathways by hypermethylation in MM 
pathogenesis, the 6 genes studied were categorized into 3 cellular pathways 
(apoptosis, cell cycle control and angiogenesis) according to their gene functions, so 
as to calculate the frequency of hypermethylation in each of the 3 cellular pathways. 
Apoptotic pathway {DAP-kinase and RAR^ showed the highest frequency of 
hypermethylation (74%，17/23), whereas cell cycle regulatory {pi6, pl5 and 
RASSFIA) and angiogenic pathway {THBS-1 only) exhibited DNA hypermethylation 
in 43% (10/23) and 39% (9/23) of primary MM respectively. 
V 
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5.5 Statistical Analyses of Primary MM 
5.5.1 Statistical Analyses Between Single Gene Hypermethylation 
and Clinical Parameters (Categorical) 
Potential associations between the 6 individual gene hypermethylation status and 
categorical clinical parameters (gender, presentation status, staging, histology, Ig 
isotypes and involvement of plasmacytoma) were investigated using Fisher's exact 
test. Results did not reveal statistically significant association between the 
individual gene methylation status and clinical parameters. However, a tendency of 
THBS-1 gene unmethylation was observed in male MM patients (9/11, p=0.060)， 
whereas unmethylation of pl6 gene was found in most of the female patients (11/12， 
p=0.060). And majority of MM patients with hypermethylated DAP-kinase were 
demonstrated with the absence of plasmacytoma (17/22). 
5.5.2 Statistical Analyses Between Single Gene Hypermethylation 
and Clinical Parameters (Non-Categorical) 
For non-categorical clinical data, Student t-test was used to analyze the potential 
associations. Results revealed following significant mean differences of numerical 
clinical parameters between MM patients with and without methylated genes. 
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Patients with DAP-kinase hypermethylation had higher Ig level (p=0.030), but lower 
Hb levels (p=0.003) than those without methylation (Figure 5.4A). WBC count was 
decreased in MM patients with THBS-1 methylation (p=0.040, Figure 5.4B). 
Conversely, MM patients with pl6 hypermethylation had increased WBC count 
(p=0.030, Figure 5.4C). For pl5 gene, MM patients showing methylation were 
demonstrated with higher platelet count compared to those showing unmethylation 
(p=0.007, Figure 5.4D). Both LDH and calcium levels were elevated in MM 







叫 1 p=0.030| ^^ 1 p=0.003 
e 6 0 - 丨 
1 4 0 - I m I 8- ^ 
‘ ： - n r ; - . 
U M U U M 
B. C. 
in,__THBS-1 pi6 
, 系 lU p=0.040| ^ ⑴ 1 
O 0 oT 
• 丨 : n n i ^ ' p h M 
- Q M . i I § 
U • M U M 
Figure 5.4 Student t-test of numerical clinical parameters between MM 
patients showing unmethylated and methylated genes. Mean values with 
standard deviation are indicated in the bar charts. U: unmethylated gene 
and M: methylated gene. A. Patients with DAP-kinase hypermethylation 
� had higher immunoglobulin (Ig) level (p=0.030) but lower hemoglobin 
(Hb) level (p=0.003). B. White blood cell (WBC) count was decreased in 
MM patients with THBS-1 methylation (p=0.040). C. MM patients with 
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Figure 5.4 Student t-test of numerical clinical parameters between MM 
patients showing unmethylated and methylated genes. Mean values with 
standard deviation are indicated in the bar charts. U: unmethylated gene 
and M\ methylated gene. D. MM patients showing pl5 hypermethylation 
were demonstrated with higher platelet count (p=0.007). E. Both lactate 
dehydrogenase (LDH) and calcium levels were elevated in MM patients 
with RASSFIA hypermethylation (p=0.007 & ;?=0.016 respectively). 
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5.5.3 Survival Analyses of Single Gene Hypermethylation 
Survival analyses between the methylation status and patient survival were 
performed. Ten patients with RAR^ hypermethylation had shorter median survival 
time (7 months, range: 1-44 months) compared to those (n=15) without methylation 
(36 months, range: 6-78 months), which corresponded to a 5-fold reduction (p=0.048 
by the Kaplan-Meier method & log-rank test, Figure 5.5A). There was also a trend 
of THBS-1 hypermethylation with shorter median survival time (p=0.061 by the 
Kaplan-Meier method & log-rank test, Figure 5.5B), such that the median survival 
time of patients with THBS-1 methylation (n=9) was 14 months (range: 5-44 months), 
and that of patients without methylation (n=13) was 37 months (range: 1-78 months). 
105 
A. 
-,2 ‘ RARjS 
<1 p=0.048(by Kaplan-Meier 
> hn method & log-rank test) 
三 0.8 -
ro 0.6 - " S 
1 “ 1 
2 0 . 4 - V V 
^ 0.2- ^ i _ » 
n � M ( n = 1 0 ) 
u I T"^  r I 




1 2 1 
p=0.061(by Kaplan-Meier 
1-0 n method & log-rank test) 
= 0 - 8 • I 
5 � . 6 - h I � [ h _ _ A _ » 
0.2 - ‘ 1 ^ 
0 J — — , > = 9 ) 1 , 
0 20 40 60 80 100 
Survival (months) 
Figure 5.5 Kaplan-Meier survival curves for MM patients according to the cancer 
gene methylation category. Probability refers to proportion surviving among MM 
patients. U denotes unmethylated gene whereas M indicates methylated gene. A. 
Patients (n二 10) showing RAR(3 methylation had significant shorter median survival 
time (7 months) than those (n=15) showing RAR(3 unmethylation (36 months) 
(p=0.048 by the Kaplan-Meier method & log-rank test). B. A trend of patients with 
THBS-1 methylation (n=9) relating to shorter median survival (14 months) compared 
to those (n=13) of THBS-1 unmethylation (37 months) (p=0.061 by the 
Kaplan-Meier method & log-rank test). 
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5.5.4 Correlation Analyses of Concurrent Hypermethylation 
To investigate the -relationship of hypermethylation status between the 6 
cancer-related genes {DAP-kinase, RA郎,THBS-1, pi6, pl5 and RASSFIA), 
Spearman correlation rank test was performed. It was shown that pl6 
hypermethylation was positively correlated to that of DAP-kinase (Spearman 
correlation coefficient, R=+0.323，p=0.043). No other statistical significant 
correlation among other genes was found. 
Potential correlations between the methylation of each gene and its modified MI 
(equaled to the number of methylated genes, excluding the gene being analyzed in 
the correlation analysis, over the number of other analyzed genes, i.e., 5 genes) were 
analyzed using Spearman correlation rank test. Results revealed that RAR^ 
methylation was positively correlated to its modified MI (R=+0.425, p=0.022). 
5.5.5 Correlation Analyses Between Concurrent Hypermethylation 
and Clinical Parameters 
Potential associations between concurrent hypermethylation and patient's 
clinicopathological data were examined. The Spearman correlation rank test 
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demonstrated a positive correlation between the MI and calcium level of MM 
patients (R=+0.424, /7=0.031). Illustrated by Student t-test, the mean calcium level 
(2.82土0.46 mmol/1) of patients with 2 to 4 genes hypermethylation was higher than 
those (2.43±0.16 mmol/1) with 0 or 1 gene hypermethylation (p=0.048, Figure 5.6). 
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. Figure 5.6 Student t-test of mean calcium level and 
number of methylated genes in MM patients. Patients 
with 2 to 4 genes hypermethylation had higher calcium 
level than those with 0 or 1 gene methylation (p二0.048). 
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CHAPTER 6 DISCUSSION 
Recently, epigenetic alterations have gained increasing recognition as important 
participants in tumor development (Rush and Plass, 2002). Demonstrated in human 
cancers, DNA hypermethylation is now considered as an alternative mechanism for 
gene inactivation (Esteller et al., 2001a). In multiple myeloma (MM), high 
incidences of hypermethylation of genes like death associated protein {DAP)-kinase, 
and pi5 were previously identified by our group, which indicated a significant 
role in MM tumorigenesis (Ng et al., 1997, 2001). In the current study, we 
analyzed the methylation status of 6 cancer-related genes concurrently in 34 primary 
MM and 6 human MM-derived cell lines using methylation-specific-polymerase 
chain reaction (MS-PCR). The frequencies of DAP-kinase, retinoic acid receptor 
beta (MR扔,thrombospondin-1 (THBS-1), pi6, pl5 and Ras association domain 
family lA (RASSFIA) hypermethylation observed in primary MM were 67%, 41%, 
39%, 28%, 27% and 14% respectively, where no methylation was detected in all 
normal peripheral blood (PB) samples. 
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6.1 Involvement of Cellular Pathways by Hypermethylation 
Carcinogenesis is a multistep process usually accompanied with genetic defects in 
multiple cellular regulatory pathways. It is the same for epigenetic lesions (Esteller, 
2002; Plass, 2002). According to their respective functions in the regulation of 
different cellular pathways, the 6 genes analyzed in the current study could be 
categorized into 3 fimctional groups, namely, apoptotic, cell cycle regulatory and 
angiogenic. 
6.1.1 Apoptotic Pathway: DAP-kinase and RARfi 
Apoptotic dysregulation was frequently found in neoplasms (Ng, 2002). It is 
particularly important in MM tumorigenesis as myeloma cells are characterized by 
prolonged survival capacity (Ng et al., 2001). The gene members in this pathway 
were the DAP-kinase and RAR^. 
DAP-kinase, as the positive mediator of apoptosis, exhibited the highest 
hypermethylation in this cohort of patients (67%, 22/33), which was similar to our 
previous finding (Ng et al., 2001). Moreover, it was reported that frequent 
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DAP-kinase hypermethylation was also found in other B-cell malignancies, 
particularly in Burkitt's lymphoma that showed 100% of hypermethylation, but not 
in T-cell malignancies (Kissil et al., 1997; Nakatsuka et al., 2000). The current 
results further supported that DAP-kinase methylation was characteristic of the 
transformed B-cell and played an important role in MM tumorigenesis. 
RARp mediates the effect of retinoic acid (RA) in the control of various cellular 
processes including apoptosis (Sirchia et al., 2000; Widschwendter et aL, 2000; 
Hayashi et al.’ 2001). In MM, we found 41% of RAR/3 hypermethylation, a 
frequency which was similar to that reported in another hematological malignancies 
natural killer cell lymphomas (47%) (Siu et al.’ 2002). Conversely, no RAR/3 
methylation was detected in pediatric acute leukemias [acute lymphoblastic leukemia 
(ALL) and acute myelogenous leukemia] (Harada et al., 2002). It can be postulated 
that the loss of RARp protein production, cannot mediate RA to down-regulate the 
major growth and survival factor IL-6 or its receptor in MM for inhibiting apoptosis 
in myeloma cells (Ogata et al., 1994; Chen et al., 1996; Gado et aL, 2000). In this 
study, the high incidence of RAR/^  hypermethylation suggested it played a significant 
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role in MM development. Furthermore, the vitamin A derived retinoid dX\-trans 
retinoic acid (ATRA) can be used as an anticancer drug, and is currently used in the 
therapy of acute promyelocytic leukemia (APL) (Degos et al., 1995; Degos and 
Wang, 2001; Honemann et al., 2001). It was shown that RARI32 promoter was 
demethylated and reexpressed during RA-induced differentiation of APL blasts and 
in the APL-derived NB4 cell line, therefore, it might be beneficial to use RA in MM 
treatment (Di Croce et al., 2002). 
6.1.2 Cell Cycle Regulatory Pathway: pl6, pl5 and RASSFIA 
pi6, pi5 and RASSFIA are regulators of cell cycle pathway (Sherr, 2000; Vos et al” 
2000; Shivakumar et al； 2002). The consequence of defects in this pathway is the 
dysregulated proliferation of plasma cells, and pl6 gene hypermethylation was 
associated with increased proliferative rate of plasma cells (Bisogna et a!., 2001). 
Inactivations of pl6 and pl5 are recognized as a pivotal event in tumor formation 
(Bisogna et al” 2001). In MM, we previously showed high incidences of pl6 (75%) 
and pl5 (67%) hypermethylation by using Southern hybridization (Ng et al., 1997). 
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Herein, using MS-PCR, we also demonstratedpl6 (28%, 8/29) andpl5 (27%, 8/30) 
genes hypermethylation. These results supported that frequent pl6 and pl5 
hypermethylation were characteristic of MM, in contrast to leukemias where only 
pl5 methylation was frequently found (Ng et al.’ 1999; Chim et al., 2002). 
However, the current study detected lower frequencies of pl6 and pl5 
hypermethylation than in our previous findings. Such a discrepancy might be 
attributed to the different methodologies adopted, and uneven patient group sampling 
such that patients were predominantly in stage III disease. In our previous study, 
Southern hybridization was used in the methylation assessment of 12 primary MM, 
whereas MS-PCR was used for the current study of 34 primary MM (Ng et al., 1997). 
It has been suggested that Southern hybridization may produce false positive or 
insignificantly positive results due to incomplete restriction enzyme digestion and 
random but non-critical methylation events (Singal and Ginder, 1999; Chim et al” 
2002,). In MS-PCR, the primer design is such that the region being amplified is 
correlated to the critical transcriptional silencing. Thus, MS-PCR analysis is based 
on the functional status of a given gene, and can provide a more biologically 
significant result. Moreover, the current results were similar to other methylation 
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studies oipl6 (20.0-26.2%) andpl5 (24.0-26.2%) genes using MS-PCR (Guillerm et 
al, 2001，2003). It. was demonstrated that similar frequencies of pl6 and pl5 
hypermethylation were found in monoclonal gammopathy of undetermined 
significance (MGUS) and MM, suggesting methylation of these genes was an early 
event and did not associate with transition from MGUS to MM (Guillerm et al., 
2001). Our current results also indicated that hypermethylation of pl6 and pl5 
were early events as they had been found in both low- and high-stage patients. 
RASSFIA is characterized as a novel Ras effector homologue from the lung cancer 
tumor suppressor locus 3p21.3. Both apoptotic and cell cycle regulatory functions 
have been proposed for RASSFIA, but its biological roles are not totally clear yet 
(Schagdarsurengin et al,, 2003). In this study, we found 14% (4/29) of RASSFIA 
hypermethylation, which was the lowest frequency being observed in the panel of 
genes examined. A similarly low frequency was found in pediatric acute leukemias 
[ALL and acute myelogenous leukemia] (15%) (Harada et al., 2002). By contrast, 
other solid tumors (thyroid, small cell lung, nasopharyngeal and gastric cancers) 
showed relatively higher frequencies of RASSFIA hypermethylation ranging from 
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71% to 95% (Byun et al., 2001; Dammann et al” 2001; Kwong et al., 2002; 
Schagdarsurengin et'al., 2002). In addition, these solid tumors were usually 
characterized with 3p loss, and DNA hypermethylation was responsible for the major 
mode of RASSFIA inactivation. However, 3p loss was not commonly observed in 
MM, there might be other mechanisms responsible for the gene inactivation that 
remained to be determined (Pratt, 2002). The role of RASSFIA as a negative Ras 
effector in a proapoptotic signaling pathway suggests that the alterations of both 
RASSFIA and Ras may be linked to each other. Mutually exclusive relationship 
between RASSFIA inactivation and K-Ras activation had been observed in pancreatic, 
colorectal and stage I lung cancers (Tomizawa et al., 2002; van Engeland et al” 2002; 
Dammann et al., 2003). Likewise, high frequency of RASSFIA methylation and 
rare Ras mutations were reported in small cell lung and nasopharyngeal carcinomas 
(Bos, 1989). Such reciprocal relationship was also consistent with the observations 
that simultaneously occurring epigenetic or genetic alterations of genes in the same 
signalling pathway were seldom observed in a single tumor. For example, 
simultaneous inactivation of retinoblastoma {Rb) andpl6 locus was negatively found 
in any tumor types (Serrano, 1997). Therefore, the low frequency of RASSFIA 
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hypermethylation detected in this study may be due to frequent N- and K-Ras 
mutations found in MM (32-47%) (Neri et al” 1989; Portier et al., 1992; Kuehl and 
Bergsagel, 2002). 
6.1.3 Angiogenic Pathway: THBS-1 
Angiogenesis, new blood vessels formation from pre-existing vessels, is obligatory 
in the enhancement of progression of solid tumors (Ribatti et al., 1999; Chavakis et 
al., 2002). Recently, angiogenesis has also gained recognition of importance in 
MM pathogenesis. It was shown that microvessel area was significantly larger in 
patients with active MM than those with non-active MM and MGUS (Ribatti et al., 
1999). To investigate for the involvement of THBS-1 in MM pathogenesis, we 
determined the methylation status of this angiogenic factor. We found that 39% of 
primary MM were hypermethylated, and in adult ALL and acute myeloid leukemia 
• ^ 
(AML), the reported frequencies were 11% and 25% respectively (Toyota et al., 2001; 
Garcia-Manero et al, 2002b). THBS-1 was suggested to possess dual functions of 
pro- or anti-angiogenesis in different human cancers, but its role in MM remained to 
be determined (Sargiaimidou et al., 2001; Tanaka et al., 2002). Herein, we showed 
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a high incidence of THBS-1 hypermethylation in MM, which was associated with 
gene silencing. Furthermore, MM had increased microvessel density as 
demonstrated in previous studies, we suggested that THBS-1 functioned as an 
angiogenic inhibitor in MM (Munshi and Wilson C，2001). The loss of THBS-1 
expression by aberrant methylation leads to the dynamic imbalance between pro- and 
anti-angiogenic factors, which favors neovascularization in the bone marrow (BM) 
microenvironment and thereby MM progression (Chavakis et al., 2002). Moreover, 
tumor-associated angiogenesis as reflected by mircovessel density is an important 
prognostic feature that can be targeted by anti-angiogenic therapy such as 
thalidomide drug treatment (Munshi and Wilson, 2001). Thalidomide has proven 
anti-angiogenic activity and remarkable efficacy in advanced and refractory MM 
(Cavenagh et aL, 2003). The use of thalidomide represents an idea for therapy that 
works primarily as a 'biological' agent rather than as a conventional cytotoxic drug 
(Hideshima and Anderson, 2002). 
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6.2 Hypermethylation-Associated Gene Silencing 
In order to verify hypermethylation is associated with transcriptional silencing, we 
have performed expression analyses before and after treatment of human 
MM-derived cell lines with the demethylating agent, 5-aza-2' -deoxycytidine 
(5-aza-CdR). Consistent with other studies, the loss of expression of DAP-kinase, 
THBS-1 and RASSFIA associated with complete methylation of the respective genes 
was reversed by demethylation treatment (Kissil et al” 1997; Li et al.’ 1999; Burbee 
et al.，2001). Also, the transcripts of DAP-kinase, THBS-1 and RASSFIA were 
detected in normal plasma cells. These data suggested that gene silencing was due 
to aberrant methylation in myeloma cells. For pl6 and pl5 genes, our group had 
previously shown transcriptional silencing by hypermethylation in cell lines (Wong 
et al., 1998). The 6 human MM-derived cell lines used in this study did not show 
complete methylation of RARJ3. However, RARJ3 inactivation by hypermethylation 
was demonstrated in gastric cancer cell line (MKN-28) (Hayashi et al., 2001). In 
conclusion, the 6 cancer-related genes studied have a strong association between 
hypermethylation and transcriptional silencing, which contributes to MM 
tumorigenesis. 
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6.3 Hypermethylation in Cell Lines and Primary MM 
In the current study,- the frequency distributions of 6 genes hypermethylation in 
human MM-derived cell lines and primary MM were different. In cell lines, pl6 
and DAP-kinase had the highest and lowest frequencies of hypermethylation 
respectively (100% versus 17%). However, in primary MM, DAP-kinase was the 
most frequent hypermethylated gene, which had a 3-fold higher frequency than being 
observed in cell lines. Meanwhile, pl6 was only detected in 28% of primary MM. 
The discrepancy of pl6 methylation between cell lines and primary MM might be 
due to in vitro artefacts generated during cell line establishment, such that pl6 was 
frequently methylated in cell lines (Ueki et aL, 2002). It was observed that when 
normal cells were passaged in culture, several normally nonmethylated genes 
become silenced by methylation (Antequera et al., 1990). In addition, during 
immortalization of normal cells, some genes that might be crucial for successful cell 
passage appeared to undergo methylation-induced silencing (Foster et al., 1998; 
Jones et al., 1990). Studies had been demonstrated that inactivation of the Rblpl6 
tumor suppressor pathway was required for immortalization of non-cancer cells 
(Jarrard et al., 1999). For instance, methylation and transcriptional silencing o f p l 6 
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was observed after several passages of human mammary epithelial cells (Foster et al” 
1998). This might explain the high prevalence of pl6 methylation in cell lines and 
discordance between cell lines and the primary MM. 
The discrepancy of DAP-kinase hypermethylation in cell lines and primary MM may 
be related to its function as a positive mediator of apoptosis (Raveh and Kimchi, 
2001). It might be postulated that the proliferative cell lines were more likely to 
have defects in cell cycle-related genes than that of apoptosis, which represented a 
sampling bias in cell lines (Ueki et al., 2002). Thus, for the cell lines, we detected 
r 
DAP-kinase hypermethylation in only one. On the contrary, DAP-kinase 
hypermethylation showed the highest frequency of hypermethylation in primary MM, 
where sampling bias towards in vitro cellular proliferativity and cultural artefacts did 
not exist. Therefore, the true status of hypermethylation in vivo could be revealed. 
The inhibition of apoptosis appeared increasingly critical in primary MM than in 
vitro cell lines, which might explain the discordance of DAP-kinase 
hypermethylation frequencies thus found. 
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6.4 Concurrent Hypermethylation 
Recently, the growing lists of hypermethylated genes prompt researchers to conduct 
hypermethylation profiling in various human cancers (Esteller et al, 2001a; Esteller, 
2002). Several single gene hypermethylation studies often on different groups of 
MM patients had been performed (Ng et al., 1997, 2001; Galm et al., 2003; Guillerm 
et al., 2003). Nevertheless, to our knowledge, there is no documentation on the 
methylation profiles in MM. In this study, we determined the hypermethylation 
profile of 6 cancer-related genes in the same cohort of 23 MM patients. 
I' 
6.4.1 DNA Hypermethylation is Common in MM 
In our previous studies, high frequencies of hypermethylation on single gene were 
shown in MM (Ng et al., 1997，2001). Herein, by examining on a limited panel of 
6 cancer-related genes, we also demonstrated high incidences of hypermethylation in 
that 91% of primary MM showed at least 1 gene hypermethylation. This indicated 
that hypermethylation was a frequent event in MM. In the hypermethylation 
profiles of other hematological malignancies, such as AML and adult ALL, high 
frequencies of at least 1 gene hypermethylation were reported (95% for 8 genes and 
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86.2% for 10 genes respectively) (Melki et al, 1999; Garcia-Manero et al., 2002b). 
The frequent hypermethylation found in MM suggested that epigenetic events might 
be a common and important mode of gene inactivation associated with MM 
transformation. 
Moreover, we found that hypermethylation in MM was not confined to a single target 
gene, but rather could occur concurrently across many different genes. In particular, 
the hypermethylation of multiple genes (2-4) occurred more frequently (56%) than 
hypermethylation of a single gene (35%), in which all of the 6 genes exhibited 
hypermethylation at various rates. For instance, DAP-kinase had the highest 
hypermethylation frequency, whereas RASSFIA was the least hypermethylated gene. 
6.4.2 Extent of DNA Hypermethylation 
The extent of hypermethylation in a profile of 1 tumor type can be represented by the 
methylation index (MI), which is a ratio of number of methylated genes to total 
number of genes being analyzed. MI is widely employed in the current methylation 
studies, particularly it is facilitating to compare different degrees of methylation 
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during multistep carcinogenesis or tumor subgroups (Toyooka et al” 2001; Kang et 
al., 2003). In this study, we revealed a mean MI of 0.32, which corresponded to 2 
genes hypermethylation in primary MM. 
6,4.3 Involvement of Cellular Pathways by DNA Hypermethylation 
Carcinogenesis is a multistep process involving dysregulation of multiple biological 
pathways (Esteller, 2002; Plass, 2002). Epigenetic alteration is an increasingly 
important mechanism of gene inactivation, which may affect all of the cellular 
pathways involved in cellular immortalization and transformation. 
r 
Hyperaiethylation-associated gene silencing was observed in various pathways such 
as cell cycle {pl6 and pi5), DNA repair [human mutL homologue 1 (hMLHl), 
0-6-methylguanine-DNA methyltransfemse {MGMY) and breast cancer 1 {BRCAl)], 
cell adherence and metastasis process [E-cadherin (CDHP), tissue inhibitor of 
metalloproteinase-3 {TIMP-3) and DAP-kinase], p53 network {pl4 and p73\ 
metabolic enzymes [glutathione S-transferase pi {GSTPl)] and the adenomatosis 
polyposis coli (APC)/p-catenin route {APC) (Esteller et al., 2001a). The 6 
cancer-related genes studied were categorized into 3 cellular pathways in order to 
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assess the relative involvements of these pathways by hypermethylation in MM 
pathogenesis. Apoptotic pathway {DAP-kinase and RARp) had the highest 
frequency of hypermethylation (74%), which was consistent with the prolonged 
survival capacity of malignant plasma cells (Ng et al., 2001). Majority of MM 
patients (74%) had apoptotic defects by DAP-kinase and RAR(3 hypermethylation. 
Forty-three percent of primary MM had hypermethylation of cell cycle-related genes 
(pi6, pl5 and RASSFIA), and the defect in angiogenic pathway {THBS-1) was 
accounted by 39%. Herein, we demonstrated the involvement by hypermethylation 
of 3 cellular pathways (apoptosis, cell-cycle control and angiogenesis) that were 
concurrently dysregulated in MM tumorigenesis. Involvement of multiple 
biological pathways was also reported in colorectal cancers, which showed 
disruption of cell cycle, DNA repair and metastasis-related process by 
hypermethylation of pi 6, hMLHl and TIMP-3 respectively. Breast cancers also 
showed pl6, BRCAl and CDHl silencing whereas lung cancers had defects of pi 6, 
MGMT and DAP-kinase genes (Esteller et al., 2001a). In conclusion, the current 
study illustrated the involvement of 3 cellular regulatory pathways in MM by 
aberrant methylation. 
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6.4.4 Concurrentpl6 and DAP-kinase Hypermethylation 
We identified the profile of hypermethylation and concurrent inactivations of 3 
cellular pathways in MM. From the studies on methylation profiles of major human 
cancers, it could be observed that hypermethylation was not a random event, but 
rather occurring in an ordered manner, such that each tumor type had its own specific 
sets of hypermethylated genes. For example, gastrointestinal tumors were 
characterized by pl6, pl4, MGMT, APC and hMLHl hypermethylation, whereas 
aerodigestive tumors showed hypermethylation of DAP-kinase, MGMT and pi6, but 
not hMLHl or pl4 (Esteller et aL, 2001a). We performed correlation analyses to 
investigate whether MM exhibit specific patterns of hypermethylation, and 
furthermore the inter-relationship of the methylation status of different genes. From 
the results, we could not define a MM-specific hypermethylation pattern. However, 
the current profile revealed a positive correlation of pl6 and DAP-kinase 
hypermethylation (Spearman correlation coefficient, R=+0.323, p=0.043), which 
indicated that they were inactivated concordantly in the primary MM. Inactivation 
of pl6 and DAP-kinase results in dysregulated cell proliferation together with 
suppressed apoptosis, constituting a common platform for the occurrence of 
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neoplastic transformation (Evan and Vousden, 2001; Raveh and Kimchi, 2001; 
Mateos et al., 2002)v Concordant correlation of pl6 and DAP-kinase methylation 
had been exhibited in bronchial brush samples from former cigarette smokers (Soria 
et al., 2002). pl6 inactivation leads to increased cell proliferation that may be 
sufficient for the establishment of preneoplastic lesions (Evan and Vousden, 2001). 
It was proposed that pl6 inactivation was an early step to immortalization by 
allowing cells to escape from immortality checkpoint (Foster et al., 1998; Wong et 
al, 1999). Meanwhile, loss of apoptosis by DAP-kinase inactivation may be 
necessary for the maintenance of neoplastic clone (Ng et al” 2001). It is because 
cells that possess inactivated DAP-kinase can escape from death signals and the 
consequent cleavage of a variety of intracellular substrates triggering cell dissolution 
(Evan and Vousden, 2001; Raveh and Kimchi, 2001). It was suggested that 
DAP-kinase inactivation was a subsequent event to inactivating pl6 (Evan and 
Vousden, 2001; Soria et al” 2002). Finding of coexisting pl6 and DAP-kinase 
hypermethylation in MM provided support to this mechanism in MM pathogenesis. 
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Concurrentpl6 andpl5 hypermethylation was commonly observed in MM, but not 
in leukemias (Ng et al” 1997; Chim et al” 2002; Guillerm et al” 2003). Similarly, 
the present study also demonstrated concurrent pl6 and pl5 hypermethylation in 
primary MM. In our previous study on 12 MM patients, we reported high incidence 
(8/12) of concomitant pl6 and pl5 hypermethylation, which was suggested to be 
pathogenetically related to the plasmacytoma development (Ng et al., 1997). On 
the contrary, findings on this cohort of 23 MM patients only displayed a relatively 
low occurrence of concurrent pl6 and pl5 methylation (2/23). Furthermore, we 
could not reveal any association between this concurrent methylation and the 
presence of plasmacytoma. As discussed in Section 6.1.2, such a discrepancy might 
be due to different experimental designs, for example, Southern hybridization versus 
MS-PCR, varied sample size and sampling distribution. 
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6.5 Clinical Applications of DNA Hypermethylation 
Recently, there are increasing researches that investigate the translational use of 
epigenetic studies in clinical areas. Concordant promoter hypermethylation 
between tumor and exfoliative tissues had been demonstrated (Esteller, 2002; Tsou et 
al., 2002). Clinical parameters such as staging and tumor size were shown to link 
to aberrant methylation (Kim et al., 2001). These findings provided a basis for 
improved diagnosis, prognosis and disease assessment. Other clinical applications 
are emerging with the accumulation of more information from further studies. Our 
current data also supported the clinical utilities of DNA hypermethylation in MM. 
I' 
6.5.1 Methylation As Tumor Markers for MM 
One of the potential clinical applications provided by the hypermethylation profiling 
is the development of molecular tumor markers. Because normal somatic cells do 
not cany the methylation signals, positive signals are contributed by tumor cells. In 
addition, the chances of finding a clinically useful methylation marker are greatly 
increased when the number of genes analyzed is increased. As a panel of genes, the 
specificity of the positive signal is further enhanced and the coverage of positive 
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methylation found in MM is maximized. However, it is ideal to obtain maximum 
coverage of a cancer-type using a minimum number of methylation markers to assay 
(Esteller et al., 2001a). From the current data, we suggested a panel of 3 genes 
{DAP-kinase, RAR(3 and THBS-1) to form the hypermethylation-based tumor markers 
for MM, covering 83% of primary MM that can be studied and followed up by 
methylation evaluation. The tumor markers can be used for clinical assessment, 
disease monitoring and minimal residual disease (MRD) detection at molecular level. 
It was showed that the detection of MRD by MS-PCR paralleled the clinical course 
(Chim et al., 2002). And in our previous study, pl5 methylation preceded 
subsequent clinical relapses of AML, ALL and acute biphenotypic leukemia (ABL) 
(Wong et al., 2000). 
6.5.2 Prognostic Implications of DNA Hypermethylation in MM 
The status of hypermethylation was shown to indicate prognostic value. 
Hypermethylation of cancer-related genes such as pl5 and DAP-kinase had 
demonstrated to correlate with shorter survival (Tang et al., 2000; Ng et al., 2001; 
Hoshino et aL, 2002). In this study, we found that RAR/3 hypermethylation was 
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significantly associated with poor prognosis (p=0.048 by the Kaplan-Meier method 
& log-rank test). Patients with methylated RARp were having shorter survival by a 
5-fold reduction. An opposing finding was reported in a subgroup of small cell 
lung cancer (SCLC) that the 2 years survival was significantly greater in patients 
with RARp methylation (Oshita et al” 2003). Additionally, we also observed a 
trend of THBS-l hypermethylation with shorter survival in MM patients (p=0.061 by 
the Kaplan-Meier method & log-rank test). On the other hand, in adult ALL, 
THBS-l hypermethylation was reported to associate with a better overall survival and 
5-year disease free survival (Garcia-Manero et aL, 2002b). The seemingly 
f 
contradictory results need to be confirmed. Taken together, the hypermethylation 
status of RARp and THBS-l might have prognostic bearing in patient's survival, 
which could act as potential prognostic markers. 
6.5.3 Associations Between DNA Hypermethylation and Clinical 
Parameters 
We analyzed the potential associations between the 6 genes hypermethylation and 
various clinical parameters in MM patients, demonstrating with statistically 
significant p-values. In the current study, DAP-kinase hypermethylation was 
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significantly associated with higher immunoglobulin (Ig) and lower hemoglobin (Hb) 
levels (p=0.030 and /7=0.003 respectively), and most patients with methylated 
DAP-kinase were demonstrated with the absence of plasmacytoma. High Ig and 
low Hb (due to anemia) levels might relate to the advanced stage of MM, and 
DAP-kinase hypermethylation was shown to associate with advanced pathologic 
stage in non-small cell lung cancer (NSCLC) (Mufti et al., 1996; Kim et al., 2001). 
These suggestions might account for the above association. 
Decreased white blood cell (WBC) count was shown in patients with THBS-1 
hypermethylation (p=0.040). By contrast, patients with pl6 hypermethylation were 
demonstrated with increased count (p=0.030). The low count of WBC may be 
attributed to plasma cell infiltration in the BM that interferes with the WBC 
production in MM patients. Alternatively, the increased WBC count may be due to 
immune response activation in against to viral and bacterial infections, as MM 
,patients are prone to infections (Mufti et al., 1996; Hoffbrand et aL, 2001; Brain and 
Durie, 2002). 
132 
Several clinicopathologic parameters that recruited in the statistical analyses have 
been suggested as prognostic markers. For instance, low platelet count 
(thrombocytopenia) are occurred in advance disease and recognised as an important 
prognostic marker in MM (Mufti et al., 1996; Hoffbrand et al., 2001; Kyle et al” 
2003). From our results, we revealed significant associations between potential 
prognostic markers and aberrant methylation. It was shown that pl5 
hypermethylation was related to the high platelet count of MM patients (p=0.007). 
Another prognostic marker that showing association with the status of 
hypermethylation was the lactate dehydrogenase (LDH) level. High LDH level is 
recognized as a poor prognostic factor and considered as a distinct clinical entity of 
MM. ‘LDH phenotype' is characterized by drug resistance and proliferative 
advantage, which will expand preferentially during disease progression (Barlogie et 
al., 1989, Suguro et al” 2000; Hatakeyama et al., 2001). In this study, we showed 
that RASSFIA hypermethylation was associated with high LDH level (p二0.007)， 
implying hypermethylated RASSFIA might confer poor prognosis. Furthermore, 
patients with RASSFIA hypermethylation showed elevated calcium level (p=0.016). 
In a study including 356 untreated MM patients, hypercalcaemia was reported as a 
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negative prognostic factor (Corso et al., 1998). Serum calcium elevation may be 
due to bone destruction by myeloma cells that in turn impair kidney functions (Mufti 
et al., 1996; Brain and Dune, 2002; Kuehl and Bergsagel, 2002). 
Besides the associations of individual gene hypermethylation, we also displayed a 
positive correlation between the calcium level and the extent of methylation (MI) 
(R=+0.424, /?=0.031). Furthermore, high Ml-patients (2-4 genes methylation) were 
having higher calcium level than the low Ml-patients (with 0 or 1 gene methylation) 
(p=0.048). As stated above, high calcium level was suggested to confer poor 
prognosis. Therefore, results might indicate that high Ml-patients have poorer 
prognosis than those low Ml-patients. It may be consistent with the fact that high 
MI represents more epigenetic defects and thereby genes inactivation, suggesting a 
link to high stage disease. 
Additionally, a modified MI (which was the number of methylated genes, excluding 
the gene being analyzed in the correlation analysis, over the number of other 
analyzed genes) was regarded as more appropriate to examine potential relationships 
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between the methylation status of individual gene and the extent of hypermethylation 
(MI). Results indicated that RA郎 methylation was positively correlated with the 
modified MI (R二+0.425，p=0.022). However, the mechanism under this 
phenomenon remains to be elucidated. In conclusion, these statistical results 
indicated that promoter hypermethylation had pathological significance. Cancerous 
patients with similar pathologies and disease stages usually display significant 
variability in clinical outcome (Laird, 2003). By the molecular characterization 
(DNA hypermethylation) and statistical analysis, it can help to define clinical 




The current study employed the MS-PCR technique to study the 5,CpG island 
hypermethylation in MM. The differences between methylated and unmethylated 
alleles that arise from sodium bisulfite treatment are the basis of MS-PCR. 
MS-PCR only required small amount of DNA and was sensitive to 0.1% of 
methylated alleles of a given CpG locus, which was particularly appropriate to adopt 
it in this study. It was because this great sensitive method could detect methylated 
alleles from primary MM even they were contaminated with normal cells without 
prior myeloma cell sorting. Moreover, since the amount of MM samples (BM 
aspirates) was limited, using MS-PCR allowed the concurrent methylation 
assessment of higher number of genes in the same MM sample. MS-PCR also 
permits the methylation status of DNA from paraffin-embedded or micro-dissected 
tissues to be studied (Herman et al., 1996). Although MS-PCR only provides a 
qualitative measure, this PCR-based assay is a rapid and easily adopted method by 
almost every molecular laboratory, therefore, it is very useful to determine or screen 
the methylation status of a large number of samples (Esteller, 2002). 
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CHAPTER 7 CONCLUSION 
In this study, we analyzed the hypermethylation of 6 cancer-related genes, namely, 
death associated protein {DAPykinase (67%, 22/33), retinoic acid receptor beta 
(RARp) (41%, 11/27)，thrombospondin-1 {THBS-1) (39%，9/23), pl6 (28%, 8/29), 
pl5 (27%, 8/30) and Ras association domain family lA {RASSFIA) (14%, 4/29) in 
34 Chinese multiple myeloma (MM) and 6 human MM-derived cell lines (ARH-77, 
IM9, RPMI-8226, NCI-H929, U266 and HS-Sultan) using 
methylation-specific-polymerase chain reaction (MS-PCR). To our knowledge, it 
was the first report demonstrating concurrent hypermethylation profile in Chinese 
MM, as well as the RAR/3, THBS-1 and RASSFIA methylation. Hypermethylation 
was shown to associate with transcriptional silencing. The high frequencies (>30%) 
of DAP-kinase, RAR^ and THBS-1 hypermethylation suggested that apoptotic and 
angiogenic dysregulations played an important role in MM tumorigenesis. 
Concurrent hypermethylation analysis demonstrated that aberrant methylation was a 
frequent event in MM, in which 91% of primary MM had at least 1 gene 
hypermethylation. The extent of hypermethylation, indicated by the methylation 
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index (MI), was equivalent to 2 genes hypermethylation (mean MI=0.32). We 
demonstrated the involvement by hypermethylation of 3 dysregulated cellular 
pathways (apoptotic, cell cycle regulatory and angiogenic) in primary MM. 
Furthermore, a positive correlation between pl6 and DAP-kinase hypermethylation 
(Spearman correlation coefficient, R=+0.323, /?=0.043) was revealed, indicating an 
interplay of cell cycle and apoptotic dysregulations in MM. 
With reference to the MM-hypermethylation profile, we suggested the 
hypermethylated DAP-kinase, RAR(3 and THBS-l to form the panel of 
hypermethylation-based tumor markers for MM, which covered 83% of primary MM. 
Survival analyses revealed significant association between hypermethylated RAR(3 
and shorter survival (p=0.048 by the Kaplan-Meier method & log-rank test), which 
suggested to possess prognostic value. We also found that DAP-kinase 
hypermethylation was related to higher immunoglobulin (p二0.030) and lower 
hemoglobin (p=0.003) levels. THBS-l (p=0.040) and pl6 (p=0.030) 
hypermethylation were coupled to the decreased and increased white blood cell 
counts respectively. Patients withpl5 hypermethylation were shown to have higher 
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platelet counts (^=0.007). RASSFIA was associated with higher lactate 
dehydrogenase (p=0;007) and calcium (p=0.016) levels. The MI was positively 
correlated to the calcium level (R=+0.424, /?=0.031), furthermore, patients with 2 to 
4 genes methylation were having higher calcium level than those with 0 or 1 gene 
methylation (p=0.048). Statistical analyses also revealed a positive correlation 
between the J14R/3 methylation and modified MI (R=+0.425,/?=0.022). 
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CHAPTER 8 FURTHER STUDIES 
Since the investigation of angiogenic defects by hypermethylation in the multiple 
myeloma (MM) was only limited to 1 gene {thromobospondin-1, THBS-1), another 
gene participating in angiogenesis could be recruited to reveal a clearer picture. 
This study demonstrated a positive correlation between pl6 and death associated 
protein {DAP)-kinase hypermethylation in a small cohort of MM patients that 
predominantly in high-stage disease. Further studies can be performed by 
increasing sample size, recruiting more low-stage patients and expanding the size of 
the genes panel, so as to determine a MM-specific hypermethylation pattern or 
classify disease subgroups. The current results indicated that the hypermethylated 
DAP-kinase, retinoic acid receptor beta (RA糊 and THBS-1 were good candidates 
to form the panel of molecular tumor markers for MM, more samples could be 
analyzed for validation in future. Moreover, longitudinal study of concordance 
between potential tumor markers methylation and clinical course in MM patients can 
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be carried out, in order to establish the feasibility of using these potential tumor 
markers in disease monitoring such as minimal residual disease (MRD) detection. 
We showed that RAR^ and THBS-1 hypermethylation were related to shorter survival. 
The chemopreventive agent retinoic acid (RA) was shown to induce RARp 
demethylation, whereas the anti-angiogenic agent thalidomide was effective in 
advanced and refractory MM treatment (Di Croce et al., 2002; Cavenagh et al, 
2003). Further studies can be performed to compare the RA or thalidomide 
treatment responses in MM patients showing positive and negative methylation, in an 
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